<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Immune function in older adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Immune function in older adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Immune function in older adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Antoine Azar, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Zuhair K Ballas, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jordan S Orange, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 22, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H5900175"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>By 2050, there will be more than 1.6 billion adults 65 years and older worldwide, making age-related diseases and conditions a growing public health concern [<a href="#rid1">1</a>]. One cannot examine immunosenescence in isolation as it is part of biological senescence that is inevitable with aging. Much of the data on immunosenescence and reversal of aging are generated in mouse models, although there are increasing human studies and clinical trials [<a href="#rid1">1</a>].</p><p>This topic will review the changes observed in different components of the immune system with aging. Normal aging is reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/14605.html" rel="external">"Normal aging"</a>.)</p><p class="headingAnchor" id="H25009826"><span class="h1">IMMUNOSENESCENCE</span><span class="headingEndMark"> — </span>Immunosenescence refers to the changes that occur in the immune system with increasing age. The study of age-related changes in immune function is a relatively new area of investigation, which is limited by incomplete understanding of the complexities of immune mechanisms in general [<a href="#rid2">2</a>]. Most research is focused on defining normal changes in immune function at the basic science level, and much of the available data are from animal studies. In addition, there are no clinical interventions that have been definitively shown to counter immunologic aging.</p><p class="headingAnchor" id="H599221216"><span class="h2">Terminology</span><span class="headingEndMark"> — </span>Terms that are routinely used in the literature of immunity in older adults include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inflammaging</strong> – Chronic low-grade (subclinical) inflammation that increases with age. It is usually associated with elevated inflammation markers [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cellular senescence</strong> – Processes that occur as cells age, including division arrest, apoptosis resistance, and the acquisition of a senescence-associated secretory phenotype (SASP) [<a href="#rid4">4</a>]. Cells undergoing these processes can be targeted in future trials aimed at slowing aging.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Senolytics</strong> – Compounds intended to eliminate senescent cells [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Senomorphics or senostatics</strong> – Compounds intended to modulate proinflammatory senescent cells [<a href="#rid5">5</a>].</p><p></p><p class="headingAnchor" id="H2650473802"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>Normal functions of the immune system include defense against infections and detection and destruction of malignant or autoreactive cells. As the immune system ages, these capabilities decline. As a result, immunosenescence is characterized by an increased risk of inflammation, infections, malignancy, and autoimmune disorders.</p><p class="headingAnchor" id="H10659458"><span class="h3">Infections</span><span class="headingEndMark"> — </span>Pneumonia and influenza are among the top 10 causes of death in individuals aged 65 years and older [<a href="#rid6">6</a>]. Nosocomial infections are also significantly increased in older adults. An age over 65 years is considered a poor prognostic marker for coronavirus disease 2019 (COVID-19) infection. Increased susceptibility to infection could be the result of decreased immunologic function, in addition to a decreased efficacy of vaccines in older adults. However, there are several other factors that are likely to contribute to increased infections in older adults, including malnutrition, comorbid conditions (eg, diabetes, chronic obstructive pulmonary disease), diminished mucosal barriers, decreased cough reflex, and mechanical changes to the urinary tract system, among others [<a href="#rid7">7</a>].</p><p>The clinical presentation of infections in older patients may be different from that in younger patients. Older adults with severe infections tend to have fewer symptoms, and fever is absent or blunted in 20 to 30 percent. This suggests a decreased ability to mount inflammatory cytokine responses in the face of infection. Signs of infection in older adults can be nonspecific and include falls, delirium, anorexia, or generalized weakness [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/d/html/14606.html" rel="external">"Approach to infection in the older adult"</a>.)</p><p>"Failure to thrive" is a term that has been extrapolated from the pediatric description. In older adults, it is used to describe a gradual decline in physical and/or cognitive function, usually accompanied by weight loss and social withdrawal that occurs without immediate explanation. Failure to thrive in older adults has been defined as a syndrome manifested by weight loss greater than 5 percent of baseline, decreased appetite, poor nutrition, and inactivity, often accompanied by dehydration, depressive symptoms, impaired immune function, and low cholesterol levels [<a href="#rid9">9</a>]. Failure to thrive is not considered a normal consequence of aging, an equivalent to dementia, or a descriptor of the later stages of a terminal disease [<a href="#rid10">10</a>]. One important, treatable cause of failure to thrive is an undetected chronic infection, such as tuberculosis, endocarditis, or bronchiectasis. (See  <a class="medical medical_review" href="/d/html/3018.html" rel="external">"Failure to thrive in older adults: Evaluation"</a> and  <a class="medical medical_review" href="/d/html/3015.html" rel="external">"Failure to thrive in older adults: Management"</a>.)</p><p class="headingAnchor" id="H4079914826"><span class="h4">Effect of malnutrition</span><span class="headingEndMark"> — </span>Adequate nutrition is fundamental to healthy aging. Malnutrition is not uncommon in older adults and is associated with increased morbidity and mortality [<a href="#rid11">11,12</a>]. In a Swedish study, malnutrition was present in 60 to 80 percent of patients over 60 years of age admitted to the hospital [<a href="#rid13">13</a>]. In general, energy requirements decrease with age due to a decline in lean body mass and decreased physical activity. Despite this, older adults are at risk for malnutrition due to dental or swallowing problems that might interfere with eating, loss of smell or taste sensations, chronic illnesses that interfere with digestion or absorption of food and increase nutritional requirements, medication side effects, depression and social isolation, functional/visual/cognitive impairments, and economic barriers to obtaining high-quality food [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/d/html/3016.html" rel="external">"Geriatric nutrition: Nutritional issues in older adults"</a>.)</p><p>Malnutrition is associated with immune defects, in particular, a decrease in T cell function [<a href="#rid15">15</a>]. Malnutrition is also associated with an increased risk of and a worse outcome with infections [<a href="#rid16">16</a>]. Deficiencies of vitamins A and E [<a href="#rid17">17</a>], vitamin C [<a href="#rid18">18</a>], vitamin B12 and folate [<a href="#rid19">19,20</a>], vitamin B6 [<a href="#rid21">21</a>], vitamin D [<a href="#rid22">22</a>], as well as zinc, <a class="drug drug_general" data-topicid="9884" href="/d/drug information/9884.html" rel="external">selenium</a>, magnesium [<a href="#rid23">23</a>], and copper [<a href="#rid24">24</a>], have been described in older adults, although the precise effects of these deficiencies on immune function are not well defined. (See <a class="local">'Nutritional supplements and diet'</a> below.)</p><p class="headingAnchor" id="H10659465"><span class="h3">Malignancy</span><span class="headingEndMark"> — </span>Cancer incidence and mortality increase markedly after age 65 years, leveling off around age 85 to 90 years. Both the innate and adaptive arms of the immune system are involved in the defense against aberrant tumor cells. Patients with primary and acquired immunodeficiency are at increased risk for certain tumors, underscoring the role of the immune system in defense against malignancy. However, carcinogenesis is a complex phenomenon, and the exact role of immunosenescence is difficult to establish. An increased mutational load and carcinogen exposure are likely other contributors to increased malignancy in older adults [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H10659472"><span class="h3">Autoimmune disorders</span><span class="headingEndMark"> — </span>There is an increase in the production of autoantibodies with age [<a href="#rid26">26</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In one study of healthy older adults, 28 percent had a positive antiphospholipid antibody, 22 percent had a positive rheumatoid factor, and 14 percent had elevated antinuclear antibodies (ANAs) [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another study of 2812 older patients found a prevalence of 17 percent for ANA, 12 percent for anti-cardiolipin antibody, 9 percent for thyroid autoantibodies, 8 percent for antineutrophil cytoplasmic antibody (ANCA), and 4 percent for cyclic citrullinated peptide (CCP) [<a href="#rid28">28</a>].</p><p></p><p>The mechanisms for heightened autoantibody production are not clear, although decreased T regulatory cell function and decreased clearance of apoptotic cells by macrophages are two potential explanations.</p><p>During the COVID-19 pandemic, a group of investigators reported that autoantibodies against type 1 interferons (IFNs), which are critical in innate immune responses to viral infection, were associated with life-threatening severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and hypothesized that anti-cytokine antibodies contributed to susceptibility to severe COVID-19 [<a href="#rid29">29</a>]. While it appeared that these autoantibodies could be induced by COVID-19, some patients appeared to have naturally occurring anti-type 1 IFN antibodies. In a subsequent publication, the same group found that autoantibodies neutralizing type I IFNs were present in the general uninfected population and that the prevalence increased significantly after the age of 70 years [<a href="#rid30">30</a>].</p><p>Like infections, autoimmune disorders, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and Sjögren's syndrome, may present with atypical symptoms in older adults. SLE can present as vague symptoms of weight loss, muscle pain, and cognitive or affective deterioration [<a href="#rid27">27</a>]. In a study of patients with RA, older patients were more likely than younger patients to present with symptoms similar to polymyalgia rheumatica and were less likely to have subcutaneous nodules or rheumatoid factor at disease onset [<a href="#rid31">31</a>]. Joint scores were also lower.</p><p class="headingAnchor" id="H10659962"><span class="h1">SPECIFIC AGE-RELATED CHANGES</span><span class="headingEndMark"> — </span>The immune system is divided into innate and adaptive immunity. Aging affects both innate and adaptive immunity, although innate immune mechanisms are better preserved overall [<a href="#rid32">32</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Innate immunity refers to immune responses that are present from birth and do not undergo gene rearrangement as a result of exposure to microorganisms/antigens, although epigenetic and evolutionary changes can modify the responses somewhat. (See  <a class="medical medical_review" href="/d/html/13572.html" rel="external">"An overview of the innate immune system", section on 'Training of innate immunity'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In contrast, adaptive immunity consists of the responses of T and B lymphocytes, which differentiate and mature during the lifetime of an individual as a result of antigen exposure. (See  <a class="medical medical_review" href="/d/html/3975.html" rel="external">"The adaptive humoral immune response"</a> and  <a class="medical medical_review" href="/d/html/3980.html" rel="external">"The adaptive cellular immune response: T cells and cytokines"</a>.)</p><p></p><p class="headingAnchor" id="H2052265003"><span class="h2">Hematopoietic stem cells</span><span class="headingEndMark"> — </span>All immune cells originate from hematopoietic stem cells (HSCs) in the bone marrow, and there is a general decline in the total bone marrow hematopoietic tissue with aging [<a href="#rid33">33</a>]. HSCs, like other cells, undergo progressive loss of telomeric deoxyribonucleic acid (DNA) with successive divisions. It is estimated that 50 to 200 base pairs of telomeric DNA are lost with each cell division [<a href="#rid34">34</a>]. The sequential loss and shortening of telomeric DNA with advancing age lead to an increase in apoptosis (noninflammatory, programmed cell death). In addition to telomere shortening, acquired defects in genomic or mitochondrial DNA also contribute to the decline in HSCs. Overall, the proliferative capacity of HSCs from older people is two to four times less than those from younger subjects [<a href="#rid33">33</a>]. Differences in regenerating capacity are particularly important during times of illness or other physiologic stress.</p><p>Production of pro-B cells is significantly decreased with aging, resulting in a smaller number of B cells leaving the bone marrow, while T cell precursors seem to be less affected [<a href="#rid35">35</a>]. In contrast, age-related changes do not affect erythroid and myeloid progenitors, and enhanced myelopoiesis is observed [<a href="#rid36">36</a>]. Other age-related changes in the bone marrow are discussed separately. (See  <a class="medical medical_review" href="/d/html/14605.html" rel="external">"Normal aging", section on 'Hematopoietic system'</a>.)</p><p class="headingAnchor" id="H10833849"><span class="h2">Innate immunity</span><span class="headingEndMark"> — </span>The innate immune system consists of epithelial barriers (skin, gastrointestinal and respiratory mucosa), macrophages, neutrophils, natural killer (NK) cells, natural killer T (NKT) cells, dendritic cells (DCs), and complement proteins. Nonspecific defense mechanisms, such as production of mucus in the proper quantity and viscosity, local antimicrobial peptides, and normal ciliary function, are also part of normal defenses. Several age-related changes in the components of the innate immune system have been characterized  (<a class="graphic graphic_table graphicRef69360" href="/d/graphic/69360.html" rel="external">table 1</a>).</p><p>Overall, although some innate immune mechanisms are decreased, other mechanisms appear to be more active in older individuals. The result of these changes is a propensity to develop chronic inflammatory states. Thus, the result of aging of the innate immune system may be most accurately characterized as a state of immune dysregulation characterized by low-grade, chronic inflammatory changes [<a href="#rid37">37</a>]. Chronic viral infections, such as cytomegalovirus (CMV) infection, may also contribute to this phenomenon, as discussed below (see <a class="local">'Immune risk profile and herpesviruses'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toll-like receptors</strong> – Toll-like receptors (TLRs) are receptors that are responsible for the recognition of pathogen-associated molecular patterns and thus play a very important role in recognizing infecting organisms. It is unclear as to whether TLR expression is reduced with aging. However, TLR function was found to be decreased in aged mice [<a href="#rid38">38</a>]. In humans, cytokine production by monocytes as a result of TLR-1/2 activation decreases with age [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/d/html/3985.html" rel="external">"Toll-like receptors: Roles in disease and therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Macrophages</strong> – Macrophages are an important first-line defense against invading microorganisms. Macrophages function by recognizing, ingesting, and killing organisms; presenting processed antigens to T cells; and releasing mediators that activate other inflammatory cells. (See  <a class="medical medical_review" href="/d/html/13572.html" rel="external">"An overview of the innate immune system", section on 'Monocytes and macrophages'</a> and  <a class="medical medical_review" href="/d/html/3982.html" rel="external">"Antigen-presenting cells", section on 'Professional APCs'</a>.)</p><p></p><p class="bulletIndent1">There is a significant decrease in bone marrow macrophage precursors with aging [<a href="#rid40">40</a>]. In addition, macrophages from aged rats and mice were found to have reduced production of nitric oxide and the reactive oxygen species that are essential for their killing activity [<a href="#rid41">41</a>]. The decreased macrophage activity in older adults may result in a longer duration of infection by extracellular bacteria, as well as delayed wound healing. Deficient production of tumor necrosis factor (TNF) alpha by skin macrophages was found to underlie impaired responses to delayed-type hypersensitivity testing with age [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neutrophils</strong> – Neutrophils are short-lived cells, important in acute inflammation and in defense against bacterial and fungal organisms. Aging does not affect the total number of neutrophil precursors in the bone marrow or the number of circulating neutrophils in the blood. However, the phagocytic ability of neutrophils is reduced in older adults as compared with younger adults. Studies of superoxide generation by neutrophils in older adult patients have reached varying conclusions, depending upon the conditions used in vitro [<a href="#rid43">43,44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Natural killer cells</strong> – NK cells are large, granular lymphocytes that secrete cytokines and are capable of destroying tumor cells and viral-infected cells. They are defined as being CD56<sup>+</sup> CD3<sup>-</sup>. Peripheral blood NK cells are comprised of approximately 10 percent CD56<sup>bright </sup>and 90 percent CD56<sup>dim</sup> subsets (see  <a class="medical medical_review" href="/d/html/3949.html" rel="external">"NK cell deficiency syndromes: Clinical manifestations and diagnosis", section on 'Biology of NK cells'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>CD56<sup>bright</sup> CD16<sup>dim</sup> NK cells function primarily in producing cytokines, such as interferon (IFN) gamma and chemokines, and have minimal cytotoxic activity.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>CD56<sup>dim</sup> CD16<sup>bright</sup> NK cells are highly cytotoxic and produce lower amounts of cytokines.</p><p></p><p class="bulletIndent2">Unlike other lymphocytes, the NK cell percentage and number tend to increase with age [<a href="#rid45">45</a>]. More than one study noted that the percentage and number of CD56<sup>bright</sup> NK cells gradually decline with age, while CD56<sup>dim</sup> NK cells progressively increase [<a href="#rid46">46-48</a>]. Consequently, the ability to produce IFN-gamma was modestly impaired in NK cells from older subjects compared with adult controls, while NK cell cytolytic activity, as well as antibody-dependent cellular toxicity, were preserved in the older population [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent2">NK cells may play an important role in controlling infections in older adults. A study on 108 older adults in nursing homes found a correlation between a low NK cell activity and both increased infection rate and death due to infections [<a href="#rid50">50</a>]. In another study, centenarians had preserved or increased NK cell activity, consistent with the concept that these cells are important for successful aging [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Natural killer T cells</strong> – NKT cells are a subset of T cells (ie, CD3<sup>+</sup>) that shares some characteristics of NK cells [<a href="#rid52">52</a>]. NKT cells are heterogeneous, but the majority express an invariant T cell receptor alpha chain encoded by V-alpha-24/J-alpha-Q gene segments (these cells are called invariant NKT cells [iNKT]) [<a href="#rid53">53</a>]. NKT cells can be a potent source of IFN-gamma and interleukin (IL) 4 and can thus modulate adaptive immune responses. Lymphocytes from older adults were reported to have a decreased percentage of iNKT, and these iNKT were more likely to secrete IL-4, rather than IFN-gamma, compared with lymphocytes from young subjects [<a href="#rid54">54-56</a>]. (See  <a class="medical medical_review" href="/d/html/3949.html" rel="external">"NK cell deficiency syndromes: Clinical manifestations and diagnosis", section on 'Biology of NK cells'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dendritic cells</strong> – DCs are the most potent antigen-presenting cells. They play a critical role in the initiation of the immune response by capturing and processing antigens and presenting the processed antigens to other immune cells. They also stimulate the immune system by secreting a number of cytokines and form an important link between innate and adaptive immunity. (See  <a class="medical medical_review" href="/d/html/3982.html" rel="external">"Antigen-presenting cells", section on 'Professional APCs'</a>.)</p><p></p><p class="bulletIndent1">The number of DCs (both myeloid and plasmacytoid DC subsets) does not seem to be affected by aging  (<a class="graphic graphic_table graphicRef69360" href="/d/graphic/69360.html" rel="external">table 1</a>) [<a href="#rid45">45</a>]. The extent of immunosenescence of human DCs remains an area of uncertainty [<a href="#rid57">57</a>]. There is a suggestion, however, that aging is associated with a numeric and functional decline in plasmacytoid but not myeloid DCs, that the TLR function in DCs from older adults may be decreased, and that such a decrease might determine the adequacy of response to influenza vaccine [<a href="#rid58">58,59</a>].</p><p></p><p class="bulletIndent1">One study suggested that, upon TLR7 stimulation, DCs from old mice have a reduced ability to upregulate costimulatory molecules and to cross-prime naïve CD8<sup>+</sup> T cells. This may have a negative impact on the generation of a robust CD8<sup>+</sup> T cell cytotoxic immune response and may provide an insight as to why severe influenza infection is common in older adults [<a href="#rid60">60</a>].</p><p></p><p class="headingAnchor" id="H10833871"><span class="h2">Adaptive immunity</span><span class="headingEndMark"> — </span>Adaptive immunity consists of T and B lymphocytes, which mediate cellular and humoral immune responses, respectively.</p><p class="headingAnchor" id="H10833693"><span class="h3">Cellular immunity and T cells</span><span class="headingEndMark"> — </span>There are several key changes that occur to T cells during aging  (<a class="graphic graphic_table graphicRef78986" href="/d/graphic/78986.html" rel="external">table 2</a>). One of the most striking changes of immunosenescence is the involution of the thymus gland.</p><p class="headingAnchor" id="H10833700"><span class="h4">Thymic involution</span><span class="headingEndMark"> — </span>Naïve T cells are generated from precursors that leave the bone marrow and migrate to the thymus for maturation. (See  <a class="medical medical_review" href="/d/html/13933.html" rel="external">"Normal B and T lymphocyte development"</a>.)</p><p>The thymus gland is most active early in life, reaches maximum size within the first year of life, and then undergoes a steady decline with age. By age seven years, the part of the thymus with active cell replication (thymopoietic space) represents less than 10 percent of the total thymic space. The functional thymic cortex and medulla are progressively replaced by fatty tissue. These changes are almost complete by age 40 to 50 years [<a href="#rid61">61</a>]. As a result of thymic involution, the number of naïve T cells exiting the thymus is significantly decreased and gets progressively lower between the age groups of 40 to 54, 55 to 69, and 70 to 90 years [<a href="#rid62">62</a>].</p><p class="headingAnchor" id="H922404"><span class="h4">Changes in T cell subsets</span><span class="headingEndMark"> — </span>An overall decline in T cell function is apparent with aging, as evidenced by a decline in T cell number and diversity and reduced T cell expansion, differentiation, and signaling intensity  (<a class="graphic graphic_table graphicRef78986" href="/d/graphic/78986.html" rel="external">table 2</a>). Specific changes include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>T cell receptor diversity dramatically decreases after age 65 years, resulting in a significantly reduced repertoire [<a href="#rid62">62</a>]. A diverse repertoire is critical for protection from a variety of new infections, especially viral infections. As a result, the ability of T cells to mount an immune response against new antigens declines with age. A study of 44 centenarians found that 84 percent had nondetectable T cell receptor excision circles (biomarkers for de novo T cell synthesis) and that these subjects had a low number of naïve T cells [<a href="#rid63">63</a>]. In contrast, numbers of terminally differentiated cells in centenarians were not different from those in young or middle-aged subjects. These findings suggest that production of new T cells is dramatically reduced in the very old, and T cell populations are largely composed of persistent long-lived lymphocytes. Age-related defects in the signaling pathways of naïve CD4 T cells have been identified [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is a decrease in the numbers of CD4 T cells, an increase in CD8 T cells, and a decrease in the costimulatory molecule CD28 with aging. Reduction in CD28 results in an impaired ability of T cells to proliferate and secrete IL-2 [<a href="#rid65">65</a>]. Because CD4 (helper) T cells are important in stimulating B cells, the ability of T cells to help B cells proliferate and produce antibodies diminishes with age [<a href="#rid66">66</a>]. (See  <a class="medical medical_review" href="/d/html/3980.html" rel="external">"The adaptive cellular immune response: T cells and cytokines", section on 'T cell activation via the two-signal model'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>T regulatory cells (Tregs) are a subset of T cells that keep the immune system "in check" by maintaining homeostasis, limiting autoimmune responses, and modulating the inflammatory response to infectious agents and tumors. There is a decrease in Treg function after the age of 50 years, which may be a contributing factor to the increase in autoimmunity and malignancy seen in older individuals  (<a class="graphic graphic_table graphicRef78986" href="/d/graphic/78986.html" rel="external">table 2</a>) [<a href="#rid67">67</a>]. (See  <a class="medical medical_review" href="/d/html/3980.html" rel="external">"The adaptive cellular immune response: T cells and cytokines", section on 'Suppression'</a>.)</p><p></p><p>Studies have been conflicting about the types of cytokines produced by aging T cells. One study showed an increased number of both T helper type 1 (Th1) and T helper type 2 (Th2) cells in older adults (70 to 90 years) and nonagenarians when compared with young individuals, with a decrease in the Th2/Th1 ratio [<a href="#rid68">68</a>]. Other studies suggested an increase in Th2 cytokines in older adults [<a href="#rid69">69,70</a>], while previous studies had suggested increased Th1 cytokines [<a href="#rid71">71</a>]. Another study examined the correlation of inflammatory cytokines (IL-6, TNF-alpha, and the 75kDa soluble TNF-alpha receptor II [sTNF-RII]) and T cell subsets with frailty in older adults [<a href="#rid72">72</a>]. Inflammatory cytokines were more closely related to frailty than were lymphocyte subpopulations. In particular, sTNF-RII levels had a high accuracy in the predictive value for frailty.</p><p class="headingAnchor" id="H10833707"><span class="h3">Humoral immunity and B cells</span><span class="headingEndMark"> — </span>B cells produce their own surface membrane immunoglobulin and differentiate into plasma cells, which then make immunoglobulin for the blood or secretions. These immunoglobulins are the mediators of humoral immunity. B cells respond to antigen exposure (ie, through infections or vaccinations) by producing antibodies, which then bind to antigens to fight concurrent infections or prevent future infections. Naïve B cells produce primarily immunoglobulin (IgM). Upon stimulation with antigen, B cells switch to the production of immunoglobulin G (IgG), immunoglobulin A (IgA), or immunoglobulin E (IgE). The ability of B cells to respond to antigens and produce antibodies is a main measure of their functional capacity. (See  <a class="medical medical_review" href="/d/html/3975.html" rel="external">"The adaptive humoral immune response"</a>.)</p><p>The numbers of B cells precursors in the bone marrow (pre-B cells), as well as peripheral B cells, decrease with age [<a href="#rid73">73</a>]. Immunoglobulin levels, on the other hand, do not change with aging and may actually increase [<a href="#rid74">74</a>]. However, quantities of specific antibodies (ie, those generated by encounters with antigens through infection or vaccination) decline with age [<a href="#rid75">75</a>]. Some studies have shown that, similar to T cells, the diversity of the B cell repertoire decreases with age. This decreased repertoire also correlated with a poor health status or "frailty" [<a href="#rid76">76</a>].</p><p class="headingAnchor" id="H10833714"><span class="h3">Memory B and T cells</span><span class="headingEndMark"> — </span>The generation of long-lasting protective memory is one of the most unique and important characteristics of the adaptive immune system. Memory is essential in allowing individuals to defend themselves from infections to which they have previously been exposed. As the thymic output declines, individuals rely more on reexpansion of experienced memory cells for defense against infections.</p><p>Memory responses to recall challenge appear to be relatively well preserved with aging compared with responses of naïve B and T cells [<a href="#rid77">77</a>]. Data suggest that memory B and T cells, once elicited by antigen during youth, are quite resilient to the impact of immunosenescence [<a href="#rid78">78,79</a>]. An example of this phenomenon was seen during the 2009 H1N1 influenza pandemic, in which older adults were better protected from H1N1 infection than middle-aged adults, probably because of the persistence of memory lymphocytes producing neutralizing cross-reactive antibodies generated in response to an H1N1 virus that circulated prior to 1957 [<a href="#rid80">80</a>]. The antibody avidity for 2009 H1 was higher in older adults than in middle-aged adults [<a href="#rid81">81</a>].</p><p>Conversely, animal studies suggest that T cell memory generated for the first time in old animals is defective [<a href="#rid82">82</a>].</p><p class="headingAnchor" id="H618644102"><span class="h3">Functional response</span><span class="headingEndMark"> — </span>T and B cells may be less responsive to stimulation with antigen in older adults. One study compared the adaptive immune responses to a neoantigen, the <a class="drug drug_general" data-topicid="8775" href="/d/drug information/8775.html" rel="external">Japanese encephalitis virus vaccine</a>, in 30 older adults (mean age 68.6 years; range 61 to 78 years) and 30 younger individuals (mean age 24.3 years; range 18 to 30 years) [<a href="#rid83">83</a>]. Antibody production and IFN-gamma production were both significantly reduced in the older adult group. Notably, CMV-seropositive older adult individuals also had significantly lower antibody titers in response to vaccination. Another study examined primary and secondary responses to hepatitis B vaccine volunteers younger and older than 60 years of age and found a decreased response to the primary but not the booster hepatitis B vaccination in older adults [<a href="#rid84">84</a>]. In addition, only the older adult group had individuals who did not respond after the three-dose primary vaccination series.</p><p class="headingAnchor" id="H921793"><span class="h1">ASSESSING IMMUNOSENESCENCE</span><span class="headingEndMark"> — </span>Immunosenescence is part of normal aging, and as such, it would be assumed to be present to varying degrees in all older adults. Assays for quantifying immunosenescence are largely research tools.</p><p class="headingAnchor" id="H3727166310"><span class="h2">Genetics versus epigenetics</span><span class="headingEndMark"> — </span>It is becoming increasingly apparent that epigenetics, or the heritable changes in phenotypes or gene expression (active versus inactive genes) that do not involve changes to the underlying DNA sequence, play a major role in many aspects of human health and disease. A recurring question in the older adults is how much of their longevity is determined by inheritance (ie, genetics) and how much is determined by lifestyle and environmental factors (ie, epigenetics).</p><p class="bulletIndent1"><span class="glyph">●</span>Studies of monozygotic twins are valuable in providing insight into the relative importance of genetics versus epigenetics. One seminal study involved an analysis of 105 pairs of healthy twins (78 monozygotic and 27 dizygotic pairs) between 8 and 82 years of age and measured 204 different parameters, including cell population frequencies, cytokine responses, and serum proteins [<a href="#rid85">85</a>]. Nonheritable influences dominated 77 percent of these parameters and almost completely dominated 58 percent of the parameters. Twin discordance increased steadily with age, suggesting that the effects of environmental exposures on the immune system are cumulative. Interestingly, the discordance was most apparent in measurements relating to T and B cells. In addition to the in vitro parameters, this study measured serologic responses to seasonal influenza vaccination and found them to be determined largely by nonheritable factors. The importance of infections across a lifespan is also illustrated by the finding that monozygotic twins discordant for cytomegalovirus (CMV) infection showed greatly reduced correlations for many immune cell frequencies, such as effector CD8 and gamma-delta T cells. (See <a class="local">'Immune risk profile and herpesviruses'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A study of centenarians suggested that successful immunologic aging results less from the presence of unique "extreme longevity genes" and more as a consequence of a series of effective immune responses over time that contain common infections, limiting the ability of viruses to cause ongoing cellular damage and tissue inflammation. In one study, the peripheral blood mononuclear cells (PBMCs) of seven subjects aged 100 to 119 years of age were found to display specific transcriptional patterns [<a href="#rid86">86</a>]. There was overexpression of several genes related to immunologic aging, including <em>STK17A</em>, a gene involved in the DNA damage response; <em>S100A4</em>, a gene in a protein family involved in age-related disease and metabolic regulation; and other genes related to antigen presentation and interferon (IFN) mediated immune activation.</p><p></p><p class="headingAnchor" id="H608470571"><span class="h3">DNA methylation</span><span class="headingEndMark"> — </span>Methyl groups can be added or removed from DNA, often in the promoter and enhancer regions of genes. DNA methylation has received significant scrutiny in the study of aging. Several studies suggested a direct correlation between overall DNA methylation and lifespan. This led to the development of so-called human DNA methylation (DNAm) clocks, including the DunedinPACE, which uses longitudinal phenotypic training data to produce a measure of the rate of biological aging [<a href="#rid87">87-89</a>]. Studies of these clocks suggest that biological age may increase over a relatively short period of time in response to stress (eg, pregnancy, major surgery, severe coronavirus disease 2019 [COVID-19]), but such increases may be transient [<a href="#rid90">90,91</a>]. Another study examined the effects of long-term caloric restriction on DNA methylation measures of biological aging [<a href="#rid92">92</a>].</p><p class="headingAnchor" id="H2432241112"><span class="h2">Proteome profile in aging</span><span class="headingEndMark"> — </span>The study of proteomics in aging is still in its infancy. Several studies have suggested that blood from young mice might reverse at least some aspects of aging in older mice [<a href="#rid93">93,94</a>]. There is a suggestion that blood factors might transfer beneficial effects of exercise on neurogenesis and cognition of the aged brain [<a href="#rid95">95</a>]. In a study of the plasma proteome profile across the human lifespan, 2925 plasma proteins were measured in blood obtained from over 4000 subjects ranging in age from 18 to 95 years old [<a href="#rid96">96</a>]. Rather than linear changes in the proteomic profile, three waves of changes were detected. These occurred during the fourth, seventh, and eight decades of life and affected different biological pathways. These waves might be associated with genetic/epigenetic modulation of clinical phenotypes.</p><p class="headingAnchor" id="H1631901603"><span class="h2">Inflammasome</span><span class="headingEndMark"> — </span>Inflammasomes are cytosolic protein complexes that serve as the framework for the activation of the same proteases that lead to activation of proinflammatory cytokines. The inflammasome gene molecules of older individuals were able to be stratified into two subsets in one study [<a href="#rid97">97</a>]. One subset had constitutive expression of proinflammatory cytokines including interleukin (IL) 1b, elevated oxidative stress, high rates of hypertension, and arterial stiffness. The other subset did not have constitutive expression of IL-1b and did not have the comorbidities of the other subset. This work may lead to future studies targeting inflammasome components to minimize inflammaging.</p><p class="headingAnchor" id="H10660551"><span class="h2">Leukocyte telomere length</span><span class="headingEndMark"> — </span>Telomeres are protein-DNA complexes, 10 to 20 kb long, characterized by tandem repeats (TTAGGG). Telomeres play a role in preventing DNA degradation by protecting the chromosome end from recombination and fusion with another telomere or DNA end. The telomere length is an indication of the cell replication history and replicative capacity of normal somatic cells [<a href="#rid98">98</a>]. Leukocyte telomere length is sometimes used as a biomarker of oxidative stress and injury [<a href="#rid99">99</a>]. Telomere length and inflammation markers were examined in a study of 1554 Japanese individuals, including 684 centenarians and semi-super centenarians (105 years or older), 167 pairs of centenarian offspring and spouses (100 to 104 years), and 536 very old (85 to 99 years) [<a href="#rid100">100</a>]. Inflammation was a more significant predictor of all-cause mortality for the very old and semi-super centenarians, respectively. Inflammation was also a better predictor than telomere length for capability and cognition. Interestingly, the inflammation score was lower in centenarian offspring compared with age-matched controls. Another study examined DNA methylation level, a general marker of epigenetic effects, in 82 semi-super centenarians, 63 of their offspring, and 47 age-matched controls and found that the offspring of semi-super centenarians had a lower epigenetic age than age-matched controls [<a href="#rid101">101</a>].</p><p class="headingAnchor" id="H25009937"><span class="h2">Immune risk profile and herpesviruses</span><span class="headingEndMark"> — </span>Although most studies look at the effects of aging on the immune system, other lines of research suggest that immunosenescence itself may be a major contributor to the process of aging. One hypothesis is that ongoing antigenic stimulation by herpesviruses (CMV or possibly also Epstein-Barr virus) may have a depleting effect on the immune system over time, which in turn contributes to the immunologic changes associated with aging and frailty [<a href="#rid102">102</a>]. Older adult women had higher CMV viral loads as compared with younger women, and frailty levels were associated with higher viral reactivation and viral loads [<a href="#rid103">103</a>].</p><p>The "immune risk profile" (IRP) is a term used to describe a combination of immunologic findings, including poor T cell proliferative response to mitogens, low numbers of B cells, inverted CD4:CD8 T cell ratio (ie, ratio &lt;1), and CMV seropositivity. The IRP has been proposed to predict survival, although results from different cohorts are not consistent, and further studies are required. Studies that support this concept include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Older adults (86 to 94 years of age) with an IRP demonstrated high mortality at two, four, and six years of follow-up [<a href="#rid104">104-106</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Studies of individuals from long-lived families and those who reached 100 years of age found a low incidence of the immune changes that comprise the IRP, suggesting that people of extreme longevity may be less susceptible to CMV-accelerated immunosenescence [<a href="#rid107">107,108</a>].</p><p></p><p>However, the findings of other studies have not supported the utility of the IRP:</p><p class="bulletIndent1"><span class="glyph">●</span>No relationship between frailty and either IRP or CMV seropositivity was found in one study of 845 persons aged 85 years and older [<a href="#rid109">109</a>]. Instead, frailty was associated with elevations in certain inflammatory markers (C-reactive protein, IL-6, tumor necrosis factor [TNF] alpha) and neutrophil counts and inversely correlated with albumin levels.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the BELFRAIL study, older adults with a phenotype of CMV seropositivity and CD4:CD8 ratio of &gt;5 (rather than &lt;1) had a higher risk of impaired physical activity [<a href="#rid110">110</a>].</p><p></p><p>A 2013 longitudinal study identified immune findings similar to the IRP in a cohort of 66-year-old individuals [<a href="#rid111">111</a>]. A five-year follow-up of the individuals in this study found that a CD4/CD8 ratio &lt;1 was associated with CMV infection and with increases in the levels of T effector memory RA (TEMRA) cells, CD8+ T cells being higher [<a href="#rid112">112</a>]. Increased levels of TEMRA and decreased levels of naïve T cells were associated with seropositivity for CMV. Interestingly, the levels of CMV IgG were stable throughout the five-year follow-up period. In a longitudinal study of 684 Japanese centenarians and semi-supercentenarians, lower indices of inflammation were a better predictor of successful aging than telomere length, and inflammation scores were lower in the centenarians' offspring compared with age-matched controls [<a href="#rid100">100</a>].</p><p class="headingAnchor" id="H922040"><span class="h1">POTENTIAL INTERVENTIONS TO COUNTER IMMUNOSENESCENCE</span><span class="headingEndMark"> — </span>Human history is replete with various strategies to increase longevity, although a more desirable goal would be increased longevity without infections, autoimmunity, or cancer. Adequate nutrition is likely essential for optimizing immune function, and there are some data indicating that regular, moderate exercise is also important. However, there are no pharmacologic therapies that have been convincingly shown to counter normal immunosenescence.</p><p class="headingAnchor" id="H1558093"><span class="h2">Nutritional supplements and diet</span><span class="headingEndMark"> — </span>Studies demonstrating that vitamin or mineral supplements can boost immune function are lacking. Available data do indicate that vitamins (A, D, E, B6, B12, folate, and C) and trace elements (<a class="drug drug_general" data-topicid="9884" href="/d/drug information/9884.html" rel="external">selenium</a>, zinc, copper, and iron) are necessary for normal immune function [<a href="#rid113">113-115</a>]. In addition, the prevalence of certain nutritional deficiencies (eg, vitamins D and B12) is sufficiently high in the geriatric population that certain supplements are indicated. However, beyond achieving the recommended daily amounts of nutrients, there are no data to suggest that further supplementation can improve immune function.</p><p>Few studies have evaluated the effect of dietary practices on specific immune functions. One study suggested that fruit and vegetable consumption improved anti-pneumococcal antibody response in subjects aged 65 to 85 years, although there were technical issues with the measurement of immune response, and more work is needed [<a href="#rid116">116</a>].</p><p>Nutritional issues in older adults are reviewed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/3016.html" rel="external">"Geriatric nutrition: Nutritional issues in older adults"</a>.)</p><p class="headingAnchor" id="H923780"><span class="h2">Exercise</span><span class="headingEndMark"> — </span>There is some evidence that long-term, moderate exercise may improve aspects of immune functioning in older adults:</p><p class="bulletIndent1"><span class="glyph">●</span>Available data suggest that CD8+ T cells and natural killer (NK) cell numbers (but not function) may be transiently elevated by acute exercise [<a href="#rid117">117,118</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One small, controlled trial (14 patients in each arm) suggested that regular aerobic exercise can increase the immune response to influenza vaccination [<a href="#rid119">119</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another small study reported that acute exercise in 20 octogenarians resulted in increased numbers of granulocytes, monocytes, and CD4+ T lymphocytes, while T cell proliferation and CD56<sup>dim</sup> NK cell numbers decreased postexercise [<a href="#rid120">120</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sixty sedentary older adult volunteers (ages 61 to 67 years) were randomized to a 40-minute supervised aerobic treadmill exercise versus resistance training three times per week for six months. The aerobic exercise group had a significant reduction in mean values of tumor necrosis factor (TNF) alpha, interleukin (IL) 6, lymphocytes (CD3, CD4, and CD8), and CD4/CD8 ratio, as well as an increase in serum IL-10, compared with the resistance training group. This suggests that longer-term aerobic exercise might contribute to reducing inflammation in older adults [<a href="#rid121">121</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The effect of cycling (as a representative of a high level of physical activity) was studied in 125 adults aged 55 to 79 years and compared with 75 age-matched older adults and 55 young adults who did not do regular exercise [<a href="#rid122">122</a>]. Cyclists had a higher frequency of naïve T cells and recent thymic emigrants compared with the inactive control group. In addition, the frequency of recent thymic emigrants in older adults who exercised was not different from young adults. Active older adults also had a lower level of IL-6, which is a pro-inflammatory cytokine, and higher levels of IL-7, which is thymoprotective. However, cyclists did not have any significant difference in the frequency of the immunosenescent CD8 T cells.</p><p></p><p>On the other hand, strenuous exercise can be immunosuppressive, and the impact of exercise probably depends upon the patient's underlying state of health, as well as the intensity and type of exercise performed [<a href="#rid123">123</a>]. In addition, studies examining the clinically relevant endpoint of reductions in the frequency of infections are needed.</p><p class="headingAnchor" id="H1067264222"><span class="h2">Stress reduction</span><span class="headingEndMark"> — </span>There are some data suggesting that chronic stress is associated with accelerated immunosenescence and that stress management therapies including psychosocial support and coping skills might reverse some features of immunosenescence [<a href="#rid124">124</a>].</p><p class="headingAnchor" id="H1557948"><span class="h2">Attention to vaccinations</span><span class="headingEndMark"> — </span>Most vaccinations that are recommended for older adults are provided to boost preexisting immune memory from previous vaccination or natural infection. Impaired vaccine response in older individuals could be due to reduced quantitative and functional memory T cells and decreased functional vaccine-specific antibodies [<a href="#rid1">1</a>]. However, some of the effective vaccine strategies described below may be able to overcome the abundance of senescent T cells. Recommendations have been issued for routine vaccination of healthy older adults  (<a class="graphic graphic_figure graphicRef82634" href="/d/graphic/82634.html" rel="external">figure 1</a>). Vaccines to protect against tetanus, diphtheria, pertussis, influenza, pneumococcal infections, and zoster are particularly relevant to individuals older than 65 years.</p><p>Other information regarding the administration of specific vaccines to older adults includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tdap</strong> – In 2010, the Advisory Committee on Immunization Practices (ACIP) began recommending that adults aged 65 years and older who anticipate having close contact with infants younger than one year of age (eg, grandparents, childcare providers, health care providers) and who have not previously received Tdap (tetanus toxoid, <strong>reduced</strong> diphtheria toxoid, and acellular pertussis) should receive a single dose of this vaccine. This is reviewed in more detail separately. (See  <a class="medical medical_review" href="/d/html/3897.html" rel="external">"Tetanus-diphtheria toxoid vaccination in adults", section on 'Indications for Td or Tdap vaccination in adults'</a> and  <a class="medical medical_review" href="/d/html/3017.html" rel="external">"Geriatric health maintenance", section on 'Immunizations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pneumococcal vaccination</strong> – Pneumococcal vaccination is recommended for adults over the age of 65 years and has been shown to be effective in this group. Recommendations for use of specific vaccines in older adults are reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/7021.html" rel="external">"Pneumococcal vaccination in adults", section on 'Approach to healthy older adults and those with predisposing medical conditions'</a>.)</p><p></p><p class="bulletIndent1">There is mounting evidence that older adults may respond better to certain adjuvants and types of vaccines [<a href="#rid125">125-127</a>]. Specifically, protein-conjugated vaccines, which have traditionally been preferred in young children, may offer advantages in older adults as well. In a study of vaccine-naïve individuals older than 70 years, subjects were initially given either the 7-valent pneumococcal conjugate vaccine (PCV-7) or 23-valent <a class="drug drug_general" data-topicid="9784" href="/d/drug information/9784.html" rel="external">pneumococcal polysaccharide vaccine</a> (PPV-23) [<a href="#rid128">128</a>]. One year after receiving the first vaccine, subjects in each group received a booster with either the PCV-7 or PPV-23 vaccine. Immune responses were compared for each of the seven serotypes common to both vaccines. Antibody concentrations and opsonophagocytic activity were higher in those who received an initial dose of PCV-7, suggesting that an initial dose of PCV-7 is likely to elicit higher and potentially more effective levels of antipneumococcal antibodies than an initial dose of PPV-23. In addition, PPV-23 induced a state of hyporesponsiveness for subsequent vaccination, which was not observed with the PCV-7 vaccine. However, a caveat of the hyporesponsiveness is that there was no control group that received PPV-23 followed by a repeat dose of PPV-23. Moreover, the hyporesponsiveness was checked only for the serotypes in PCV-7 and not all of the serotypes in PPV-23. This is an important point given the clinical reports suggesting that, in children, PCV-7, while inducing protection against the seven serotypes, may be associated with higher susceptibility to infection with the nonvaccine serotypes [<a href="#rid129">129,130</a>].</p><p></p><p class="bulletIndent1">Data are inconsistent regarding the effectiveness of pneumococcal vaccination in the "older old," in terms of antibody generation or incidence of invasive pneumococcal disease. In one study, persons &gt;85 years of age generated adequate antibody responses to the PPV-23 vaccine [<a href="#rid131">131</a>], while in another, persons &gt;80 years of age demonstrated a decreased IgG antibody response to PPV-23, and the opsonophagocytic activity of these antibodies was relatively poor [<a href="#rid132">132</a>]. A third study of patients &gt;80 years of age found that vaccination with PPV-23 did not significantly reduce invasive pneumococcal disease [<a href="#rid133">133</a>].</p><p></p><p class="bulletIndent1">Of note, even the effectiveness of the conjugated pneumococcal vaccine may be reduced with age, as suggested in a study of immunocompetent adults aged ≥65 years. This study suggested that the efficacy of the <a class="drug drug_general" data-topicid="9906" href="/d/drug information/9906.html" rel="external">13-valent pneumococcal conjugate vaccine</a> (PCV-13) in preventing community-acquired pneumonia or invasive pneumococcal disease declined with increasing age, from 65 percent in 65 year olds to 40 percent in 75 year olds [<a href="#rid134">134</a>]. In another study, overall efficacy of PPV23 was 27 percent in individuals older than 65 years, with higher effectiveness in those without underlying medical conditions [<a href="#rid135">135</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Influenza</strong> – Vaccine studies suggest that older individuals have significantly reduced influenza-specific antibody responses compared with young adults and/or fail to maintain durable antibody titers. In addition, antibodies in older individuals have a lower ability to neutralize infection [<a href="#rid136">136</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Herpes zoster</strong> – In 2017, the ACIP recommended the two-dose <a class="drug drug_general" data-topicid="115351" href="/d/drug information/115351.html" rel="external">recombinant zoster vaccine</a> (RZV) for adults ≥50 years, including those individuals who previously received the <a class="drug drug_general" data-topicid="10340" href="/d/drug information/10340.html" rel="external">zoster vaccine live</a> (ZVL) and those who have a history of herpes zoster [<a href="#rid137">137</a>]. The efficacy or RZV in preventing herpes zoster was high regardless of age: 96.6 percent (50 to 59 years), 97.4 percent (60 to 69 years), and 91.3 percent (≥70 years). In persons aged ≥70 years, vaccine efficacy was 97.6 percent in the first year and 84.7 percent for the remaining three years of the study. Efficacy for prevention of postherpetic neuralgia was 91.2 percent (≥50 years) and 88.8 percent (≥70 years). RZV estimates of efficacy against herpes zoster were higher than ZVL estimates in all age categories, the difference being most pronounced among recipients aged ≥70 years [<a href="#rid138">138</a>]. The use of a novel VZV subunit plus adjuvant in the RZV seems to be promising in overcoming age-related reductions in immune responses. (See  <a class="medical medical_review" href="/d/html/8343.html" rel="external">"Vaccination for the prevention of shingles (herpes zoster)", section on 'Recombinant zoster vaccine'</a>.)</p><p></p><p class="headingAnchor" id="H10662215"><span class="h3">Use of higher-dose vaccines</span><span class="headingEndMark"> — </span>Increasing the dose of certain vaccines may improve effectiveness in older adults. A study of patients with asthma suggested that patients aged 60 years and older produced adequate levels of seroprotective antibody to H1N1 vaccine in response to a 30 mcg dose but not a 15 mcg dose [<a href="#rid125">125</a>]. In response to this and other studies showing that the conventional vaccine produced marginal protection in older adults, higher-dose vaccines were developed specifically for patients over the age of 65 years. (See  <a class="medical medical_review" href="/d/html/7007.html" rel="external">"Seasonal influenza vaccination in adults", section on 'Formulations'</a>.)</p><p class="headingAnchor" id="H10662079"><span class="h3">Role of vaccine boosters</span><span class="headingEndMark"> — </span>In a study evaluating pre- and postimmunization titers for the tetanus, diphtheria, pertussis, and polio vaccines in 252 older adults compared with a group of younger adults, protective titers were lower for the inactivated vaccines compared with the live polio vaccine [<a href="#rid139">139</a>]. For the inactivated vaccines, postimmunization titers were significantly higher in patients with higher preimmunization titers, indicating that routine booster programs for these vaccines could help achieve better protection in older adults.</p><p class="headingAnchor" id="H923902"><span class="h2">Investigational vaccine techniques</span><span class="headingEndMark"> — </span>There are several other strategies that could improve vaccine response in older adults:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use of different adjuvants and vaccine formulations</strong> – Older adults may respond better to certain adjuvants and types of vaccines [<a href="#rid125">125-127</a>]. As an example, young children are believed to respond to protein-conjugated vaccines better than polysaccharide vaccines, and conjugate vaccines have been traditionally used in children. However, these preparations may offer advantages in older adults as well. In a study of vaccine-naïve individuals older than 70 years, subjects were initially given either PCV-7 or PPV-23 [<a href="#rid128">128</a>]. One year after receiving the pneumococcal vaccine, subjects in each group received a booster with either the PCV-7 or PPV-23 vaccine. Immune responses were compared for each of the seven serotypes common to both vaccines. Antibody concentrations and opsonophagocytic activity were higher in those who received an initial dose of PCV-7. The authors concluded that an initial dose of PCV-7 is likely to elicit higher and potentially more effective levels of antipneumococcal antibodies than is PPV-23. In addition, PPV-23 induced a state of hyporesponsiveness for subsequent vaccination, which was not observed with the PCV-7.</p><p></p><p class="bulletIndent1">The use of an adjuvant (AS03) in the trivalent influenza vaccine in adults ≥65 years resulted in a higher frequency of CD4 T cells specific to the three vaccine strains [<a href="#rid140">140</a>].</p><p></p><p class="bulletIndent1">Clinical trials also suggest that Toll-like receptor (TLR) ligands can be safe and effective vaccine adjuvants, but studies are needed to assess their efficacy in older adults [<a href="#rid141">141</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refining vaccination schedules</strong> – Another general strategy for optimizing the response to vaccines that create long-lasting immunity is to administer these earlier in life, when the immune system can create a more vigorous and lasting memory response [<a href="#rid139">139</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Changing the routes of administration</strong> – At least one study documented higher protective antibody levels to influenza vaccine in older adults with intradermal, rather than intramuscular, administration [<a href="#rid142">142</a>]. However, specific preparations are needed for intradermal administration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Novel vaccines</strong> – Vaccines to prevent chronic viral infections, such as cytomegalovirus (CMV), Epstein-Barr virus, herpes simplex virus, and perhaps also human immunodeficiency virus (HIV) are of interest in the field of immunosenescence because these chronic infections are believed to contribute to the chronic inflammatory changes of aging, as well as to "immunologic exhaustion" [<a href="#rid12">12</a>].</p><p></p><p class="headingAnchor" id="H923265"><span class="h2">Cytokine therapies</span><span class="headingEndMark"> — </span>Recombinant IL-7 is under investigation as an agent to increase thymic output of T cells [<a href="#rid143">143</a>]. The use of this drug in aged mice resulted in reversal of thymic atrophy and increased thymic output. Simian IL-7 in aged rhesus macaques resulted in increased numbers of naïve CD4 and CD8 cells, central memory CD8 T cells, and T cell receptor excision circles, which are biomarkers for de novo T cell synthesis.</p><p>A phase I study of recombinant human IL-7 (rhIL-7) done on 16 human subjects with refractory cancer (age 20 to 71 years) suggested that rhIL-7 disproportionately increased the numbers of naïve and central memory cells (but not effector T cells). CD8+ T cell repertoire diversity also increased. These effects were age independent and persisted after therapy (for the study duration of 28 days) [<a href="#rid144">144</a>]. It has also been studied in patients with HIV infection [<a href="#rid145">145</a>], although not in normal-aging adults.</p><p class="headingAnchor" id="H3076299778"><span class="h2">Investigational pharmacologic interventions</span><span class="headingEndMark"> — </span>Drugs that have been evaluated for possible antiaging effects include mammalian (mechanistic) target of rapamycin (mTOR) inhibitors, immune checkpoint inhibitors, statins, and others.</p><p class="headingAnchor" id="H144021931"><span class="h3">mTOR inhibitors</span><span class="headingEndMark"> — </span>Agents that inhibit the mammalian (mechanistic) target of rapamycin (mTOR) suppress T cell proliferation and proliferative responses induced by several cytokines. These drugs have been studied for their effects on lifespan (in animal models) and immune function, although it remains to be seen if the findings apply to humans.</p><p class="bulletIndent1"><span class="glyph">●</span>Animal studies have found that mTOR inhibitors variably extend lifespan and partially reverse aging to immune cells. Studies in mice showed that the mTOR inhibitor rapamycin extended lifespan by 9 to 14 percent, even when treatment was started later in life, an effect that was sex dependent and unrelated to dietary restriction [<a href="#rid146">146,147</a>]. However, a study in marmosets found that long-term (14 months) administration of rapamycin did not increase lifespan [<a href="#rid148">148</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Human studies of mTOR inhibitors suggest that mTOR inhibitors may counter some components of immunosenescence. In a single-blind, placebo-controlled trial, 218 volunteers &gt;65 years of age with no unstable medical conditions were randomized to receive placebo or one of three doses of an oral mTOR inhibitor [<a href="#rid149">149</a>]. Subjects were treated for six weeks, followed by a two-week hiatus, and then given influenza vaccine. The mTOR inhibitor enhanced the response to influenza vaccine by approximately 20 percent and reduced the percentage of CD4 and CD8 lymphocytes that expressed the programmed death-1 (PD-1) receptor. A separate study in mice showed that aged mice have increased numbers of exhausted T cells and that T cell function could be partially restored by in vitro blockade of the PD-1 pathway [<a href="#rid150">150</a>].</p><p></p><p class="headingAnchor" id="H4040908624"><span class="h3">Immune checkpoint inhibitors</span><span class="headingEndMark"> — </span>Senescent human cells express PD-1 ligand (PD-L1), which makes them resistant to elimination by T cells, which express the receptor for PD-L1, PD-1. PD-L1+ cells accumulate with age and contribute to inflammaging [<a href="#rid151">151</a>]. Administration of anti PD-1 antibody to naturally aging mice reduced the number of immunosenescent cells, suggesting that elimination of PD-L1+ cells might be able to reduce or reverse inflammaging. This finding also raises the question of whether older adults respond differently to immune checkpoint inhibitors used for many types of cancer. Few studies have addressed this question, although one meta-analysis did not detect a difference in overall survival between younger and older patients receiving these agents [<a href="#rid152">152</a>].</p><p class="headingAnchor" id="H338924168"><span class="h3">Statins</span><span class="headingEndMark"> — </span>Preliminary studies suggest that statin drugs may have a beneficial effect of the process of aging by two mechanisms: an antiinflammatory effect and an effect on telomere shortening. However, further study is needed before statins can be recommended as antiaging therapy.</p><p>Statins are known to have antiinflammatory effects [<a href="#rid153">153,154</a>]. A rat model suggested that <a class="drug drug_general" data-topicid="8949" href="/d/drug information/8949.html" rel="external">atorvastatin</a> prevents age-related and amyloid B-induced microglial activation by blocking interferon (IFN) gamma release from NK cells in the brain [<a href="#rid155">155</a>]. Other evidence suggests that statins may have antiaging effects that are linked to their ability to inhibit telomere shortening by reducing oxidative telomeric DNA damage, as well as by a telomere capping mechanism [<a href="#rid156">156</a>]. (See <a class="local">'Leukocyte telomere length'</a> above.)</p><p class="headingAnchor" id="H1364946759"><span class="h3">Metformin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">Metformin</a> is widely used for glucose control in type 2 diabetes. It acts by increasing the activity of AMP-activated protein kinase (AMPK) [<a href="#rid157">157</a>]. In a retrospective observational study, the survival of patients with type 2 diabetes treated with metformin or sulfonylureas was examined and compared with age-matched controls [<a href="#rid158">158</a>]. Those treated with metformin had longer survival than matched controls without diabetes and also longer survival than those with diabetes receiving sulfonylureas. Several clinical trials are either underway or getting ready to start with the goal of examining the effect of metformin on lifespan, frailty, and immunosenescence [<a href="#rid159">159,160</a>].</p><p class="headingAnchor" id="H18824197"><span class="h1">EVALUATION OF IMMUNE FUNCTION IN OLDER ADULTS</span><span class="headingEndMark"> — </span>Many older adults have mild degrees of immunosuppression as a result of immunosenescence, and it can be difficult to determine if an evaluation of immune function is indicated. However, immune dysfunction would present with the same types of disorders in an older adult as in a younger adult, and clinicians should be vigilant for certain patterns:</p><p class="bulletIndent1"><span class="glyph">●</span>The hallmark of a weak immune system is recurrent infections. In patients of any age, several characteristics of infections raise the suspicion of an immunodeficiency: higher-than-expected frequency, severity, duration, complications, and infections with unusual organisms. However, the presentation of infections in older individuals can be subtle and atypical. In older adults, unexplained bronchiectasis may be a sign that the patient experienced multiple pulmonary infections throughout life.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The combination of infectious, autoimmune, and malignant disease is an indicator of immune dysregulation and should prompt consideration of an immune evaluation in a patient of any age.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic diarrhea or malabsorption and poor wound healing are other potential presentations of immunodeficiency.</p><p></p><p>The approach to a patient with possible immunodeficiency begins with the consideration of whether a primary or secondary immune problem is more likely. In all age groups, secondary causes of immunodeficiency are more common than primary causes, and this is especially true in older adults.</p><p class="headingAnchor" id="H18824070"><span class="h2">Secondary causes of immunodeficiency</span><span class="headingEndMark"> — </span>Secondary causes of immunodeficiency are much more common than inborn errors of immunity (primary immunodeficiency disorders) in older adults. Common causes of secondary immunodeficiency include:</p><p class="bulletIndent1"><span class="glyph">●</span>Malnutrition (see  <a class="medical medical_review" href="/d/html/3016.html" rel="external">"Geriatric nutrition: Nutritional issues in older adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Malignancy and drugs to treat malignancy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunosuppressive drugs</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunomodulatory agents (eg, <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> [affecting B cells], <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a>, <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a>, <a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">anakinra</a> [affecting cellular immunity]) (see  <a class="medical medical_review" href="/d/html/3939.html" rel="external">"Secondary immunodeficiency induced by biologic therapies", section on 'Rituximab'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drug-induced hypogammaglobulinemia (eg, certain antiseizure medications) (see  <a class="medical medical_review" href="/d/html/3914.html" rel="external">"Primary humoral immunodeficiencies: An overview", section on 'Differential diagnosis'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Protein loss (especially if presenting with low IgG but normal IgA and IgM; eg, nephrotic syndrome, protein-losing enteropathy)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Metabolic disease (diabetes, severe liver disease, uremia)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Human immunodeficiency virus (HIV) infection</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Functional or surgical asplenia</p><p></p><p>Evaluation of the immune system in older adults therefore starts with screening for causes of secondary immunodeficiency. As in any area of medicine, the most important initial evaluation is a thorough history: detailed history regarding infections (location, complications, frequency, etc), weight loss (suggesting malnutrition, malignancy, or chronic inflammatory disease), a review of any chronic medical problems (eg, poorly controlled diabetes mellitus), and detailed medication history (including immunosuppressive and immunomodulatory medications, as well as antiseizure medications, with particular attention to drug interactions).</p><p class="headingAnchor" id="H18824077"><span class="h2">Primary causes of immunodeficiency</span><span class="headingEndMark"> — </span>Although inborn errors of immunity commonly present in childhood or early adulthood, they can initially present in older adults or may be recognized for the first time in later life, once multiple manifestations of immune dysfunction have developed. The most common example would be common variable immunodeficiency. Specific antibody deficiency (ie, the inability to mount an antipolysaccharide antibody response) may also be diagnosed later in life. (See  <a class="medical medical_review" href="/d/html/3928.html" rel="external">"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults"</a> and  <a class="medical medical_review" href="/d/html/3965.html" rel="external">"Specific antibody deficiency"</a>.)</p><p class="headingAnchor" id="H18824084"><span class="h2">Initial screening tests for immunodeficiency</span><span class="headingEndMark"> — </span>Once suspected, evaluation for immunodeficiency in older adults is similar to that in younger adults, with the exception that the emphasis should be on underlying malignancies and other causes of secondary immunodeficiency. We suggest the following initial tests to evaluate immune function in an older adult:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count with differential and smear. Total circulating numbers of white blood cells as well as the differential of the white blood cell count do not change significantly with age.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Creatinine, electrolytes, liver function tests, blood glucose.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urinalysis (to detect proteinuria).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Total serum protein, prealbumin, albumin, cholesterol (decreased in malnutrition).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Plasma zinc and <a class="drug drug_general" data-topicid="9884" href="/d/drug information/9884.html" rel="external">selenium</a> levels.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum IgG, IgM, IgA, IgE. Levels of IgG, IgA, and IgM typically do not change with age and may increase slightly. An elevated IgE level is usually seen in atopic diseases but can also serve as a surrogate marker for a skewing of the immune system toward a T helper type 2 (Th2) response, which would be less efficient at fighting infections. Moreover, IgE can be elevated in parasitic infestations, lymphomas, HIV, and some inflammatory diseases. (See  <a class="medical medical_review" href="/d/html/5542.html" rel="external">"The biology of IgE"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lymphocyte subsets; this includes enumeration of T, B, and natural killer (NK) cells via flow cytometry.</p><p></p><p>Expected changes are discussed above (see <a class="local">'Adaptive immunity'</a> above). The interpretation of immunologic studies is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3903.html" rel="external">"Laboratory evaluation of the immune system"</a>.)</p><p class="headingAnchor" id="H18825270"><span class="h3">Vaccine response</span><span class="headingEndMark"> — </span>The ability of a patient to respond to vaccination is the next step in evaluating immune function. Response to both protein and polysaccharide antigens is assessed. (See  <a class="medical medical_review" href="/d/html/3903.html" rel="external">"Laboratory evaluation of the immune system", section on 'Measurement of antibody function'</a>.)</p><p>Selective polysaccharide nonresponse is the most common form of functional antibody defect and is best demonstrated by an inability to respond to 23-valent <a class="drug drug_general" data-topicid="9784" href="/d/drug information/9784.html" rel="external">pneumococcal polysaccharide vaccine</a> (PPV-23). However, a clear definition of a normal response to PPV-23 in patients &gt;65 years of age has not been established, and studies are somewhat conflicting, although most have found that responses to PPV-23 are diminished. Relevant studies include the following [<a href="#rid131">131-133,161-164</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>One group reported that the 30-day response and five-year persistence of antibodies to <a class="drug drug_general" data-topicid="9784" href="/d/drug information/9784.html" rel="external">pneumococcal polysaccharide vaccine</a> serotypes was preserved irrespective of age [<a href="#rid164">164</a>]. Similarly, in another study of persons &gt;85 years of age, subjects generated adequate antibody responses to the PPV-23 vaccine [<a href="#rid131">131</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In contrast, another study found that persons &gt;80 years of age demonstrated a decreased IgG antibody response to PPV-23, and the opsonophagocytic activity of these antibodies was relatively poor [<a href="#rid132">132</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Frailty appeared to impact the quantitative response to vaccines more than numeric age in one report [<a href="#rid154">154,165</a>]. Older adults who responded to the vaccine with titers that were slightly lower than protective sometimes generated protective titers after a second (booster) dose. In this clinical setting, it is reasonable to boost with another dose of PPV-23. However, antibody titers before and after immunization should be compared in order to ensure adequate response and to exclude specific antibody deficiency.</p><p></p><p>If no abnormalities are uncovered by the testing described above and suspicion is still high for an immunodeficiency, then further work-up would be targeted toward underlying malignancies, presenting symptoms, and less common forms of inborn errors of immunity.</p><p class="headingAnchor" id="H18136408"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunosenescence</strong> – The term "immunosenescence" refers to the changes that occur in the immune system with advancing age. The clinical consequences of immunosenescence include an increased risk of infections, malignancy, and autoimmune disorders. Malnutrition is relatively common among older adults and can also contribute to declining immune function. (See <a class="local">'Immunosenescence'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Age-related changes in immune processes</strong> – Aging affects both innate and adaptive immunity, although adaptive processes are affected more dramatically. (See <a class="local">'Specific age-related changes'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Innate immunity</strong> – The innate immune system consists of epithelial barriers, antimicrobial peptides and mucus, as well as macrophages, neutrophils, natural killer (NK) cells, natural killer T (NKT) cells, dendritic cells (DCs), and complement proteins. Some innate immune mechanisms decline with age, while others appear to become more active. The clinical consequence of this increased activity results in a state of immune dysregulation characterized by low-grade, chronic proinflammatory changes. (See <a class="local">'Innate immunity'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adaptive immunity</strong> – The adaptive immune system consists of B and T cell responses. With aging, naïve T and B cells decline, while the functions of memory cells are relatively preserved. Immunoglobulin levels do not change or sometimes increase, but specific antibody production declines, and the ability of B and T cells to interact and respond vigorously to vaccinations and new infections becomes limited. (See <a class="local">'Adaptive immunity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation of immunologic aging</strong> – Immunosenescence is not routinely measured in clinical practice, although several parameters, such as leukocyte telomere length and the "immune risk profile," are used in research settings. (See <a class="local">'Assessing immunosenescence'</a> above.)</p><p></p><p class="bulletIndent1">Evaluation of the immune system in older adults is similar to that in younger adults, with a greater emphasis on disorders leading to secondary immunodeficiency. (See <a class="local">'Evaluation of immune function in older adults'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lack of therapies</strong> – There are no specific therapies that have been convincingly shown to counter normal immunosenescence. However, adequate nutrition is important, and regular, moderate exercise may also be beneficial. Research is ongoing in strategies to create vaccines that are more effective in older adults. In addition, vaccination against common herpesviruses, such as cytomegalovirus (CMV) and Epstein-Barr virus, may someday limit the contribution of these viruses to "immunologic exhaustion." (See <a class="local">'Potential interventions to counter immunosenescence'</a> above.)</p><p></p><p class="headingAnchor" id="H651943952"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges E Richard Stiehm, MD, who contributed as a Section Editor to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Gustafson CE, Kim C, Weyand CM, Goronzy JJ. Influence of immune aging on vaccine responses. J Allergy Clin Immunol 2020; 145:1309.</a></li><li><a class="nounderline abstract_t">Agarwal S, Busse PJ. Innate and adaptive immunosenescence. Ann Allergy Asthma Immunol 2010; 104:183.</a></li><li><a class="nounderline abstract_t">Franceschi C, Garagnani P, Parini P, et al. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol 2018; 14:576.</a></li><li><a class="nounderline abstract_t">Kirkland JL, Tchkonia T. Cellular Senescence: A Translational Perspective. EBioMedicine 2017; 21:21.</a></li><li><a class="nounderline abstract_t">Kang C. Senolytics and Senostatics: A Two-Pronged Approach to Target Cellular Senescence for Delaying Aging and Age-Related Diseases. Mol Cells 2019; 42:821.</a></li><li class="breakAll">https://www.cdc.gov/injury/wisqars/LeadingCauses.html. (Accessed on September 07, 2018).</li><li><a class="nounderline abstract_t">Gavazzi G, Krause KH. Ageing and infection. Lancet Infect Dis 2002; 2:659.</a></li><li><a class="nounderline abstract_t">Norman DC. Fever in the elderly. Clin Infect Dis 2000; 31:148.</a></li><li><a class="nounderline abstract_t">Robertson RG, Montagnini M. Geriatric failure to thrive. Am Fam Physician 2004; 70:343.</a></li><li><a class="nounderline abstract_t">Egbert AM. The dwindles: failure to thrive in older patients. Nutr Rev 1996; 54:S25.</a></li><li><a class="nounderline abstract_t">Drey M, Kaiser MJ. [Malnutrition in the elderly]. Dtsch Med Wochenschr 2011; 136:176.</a></li><li><a class="nounderline abstract_t">Fülöp T, Larbi A, Hirokawa K, et al. Immunosupportive therapies in aging. Clin Interv Aging 2007; 2:33.</a></li><li><a class="nounderline abstract_t">Persson MD, Brismar KE, Katzarski KS, et al. Nutritional status using mini nutritional assessment and subjective global assessment predict mortality in geriatric patients. J Am Geriatr Soc 2002; 50:1996.</a></li><li><a class="nounderline abstract_t">Volkert D, Saeglitz C, Gueldenzoph H, et al. Undiagnosed malnutrition and nutrition-related problems in geriatric patients. J Nutr Health Aging 2010; 14:387.</a></li><li><a class="nounderline abstract_t">Kawakami K, Kadota J, Iida K, et al. Reduced immune function and malnutrition in the elderly. Tohoku J Exp Med 1999; 187:157.</a></li><li><a class="nounderline abstract_t">Chandra RK. Nutrition and the immune system from birth to old age. Eur J Clin Nutr 2002; 56 Suppl 3:S73.</a></li><li><a class="nounderline abstract_t">Cunha DF, Cunha SF, Unamuno MR, Vannucchi H. Serum levels assessment of vitamin A, E, C, B2 and carotenoids in malnourished and non-malnourished hospitalized elderly patients. Clin Nutr 2001; 20:167.</a></li><li><a class="nounderline abstract_t">Heseker H, Schneider R. Requirement and supply of vitamin C, E and beta-carotene for elderly men and women. Eur J Clin Nutr 1994; 48:118.</a></li><li><a class="nounderline abstract_t">Clarke R, Refsum H, Birks J, et al. Screening for vitamin B-12 and folate deficiency in older persons. Am J Clin Nutr 2003; 77:1241.</a></li><li><a class="nounderline abstract_t">Andrès E, Loukili NH, Noel E, et al. Vitamin B12 (cobalamin) deficiency in elderly patients. CMAJ 2004; 171:251.</a></li><li><a class="nounderline abstract_t">Spinneker A, Sola R, Lemmen V, et al. Vitamin B6 status, deficiency and its consequences--an overview. Nutr Hosp 2007; 22:7.</a></li><li><a class="nounderline abstract_t">Gloth FM 3rd, Gundberg CM, Hollis BW, et al. Vitamin D deficiency in homebound elderly persons. JAMA 1995; 274:1683.</a></li><li><a class="nounderline abstract_t">Vaquero MP. Magnesium and trace elements in the elderly: intake, status and recommendations. J Nutr Health Aging 2002; 6:147.</a></li><li><a class="nounderline abstract_t">Carmel R. Nutritional anemias and the elderly. Semin Hematol 2008; 45:225.</a></li><li><a class="nounderline abstract_t">Malaguarnera L, Cristaldi E, Malaguarnera M. The role of immunity in elderly cancer. Crit Rev Oncol Hematol 2010; 74:40.</a></li><li><a class="nounderline abstract_t">Aprahamian T, Takemura Y, Goukassian D, Walsh K. Ageing is associated with diminished apoptotic cell clearance in vivo. Clin Exp Immunol 2008; 152:448.</a></li><li><a class="nounderline abstract_t">Ramos-Casals M, Brito-Zerón P, López-Soto A, Font J. Systemic autoimmune diseases in elderly patients: atypical presentation and association with neoplasia. Autoimmun Rev 2004; 3:376.</a></li><li><a class="nounderline abstract_t">Iseme RA, McEvoy M, Kelly B, et al. A Cross-Sectional Study of the Association between Autoantibodies and Qualitative Ultrasound Index of Bone in an Elderly Sample without Clinical Autoimmune Disease. J Immunol Res 2018; 2018:9407971.</a></li><li><a class="nounderline abstract_t">Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 2020; 370.</a></li><li><a class="nounderline abstract_t">Bastard P, Gervais A, Le Voyer T, et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol 2021; 6.</a></li><li><a class="nounderline abstract_t">Deal CL, Meenan RF, Goldenberg DL, et al. The clinical features of elderly-onset rheumatoid arthritis. A comparison with younger-onset disease of similar duration. Arthritis Rheum 1985; 28:987.</a></li><li><a class="nounderline abstract_t">Weiskopf D, Weinberger B, Grubeck-Loebenstein B. The aging of the immune system. Transpl Int 2009; 22:1041.</a></li><li><a class="nounderline abstract_t">Geiger H, Rudolph KL. Aging in the lympho-hematopoietic stem cell compartment. Trends Immunol 2009; 30:360.</a></li><li><a class="nounderline abstract_t">Vaziri H, Dragowska W, Allsopp RC, et al. Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proc Natl Acad Sci U S A 1994; 91:9857.</a></li><li><a class="nounderline abstract_t">Cancro MP, Hao Y, Scholz JL, et al. B cells and aging: molecules and mechanisms. Trends Immunol 2009; 30:313.</a></li><li><a class="nounderline abstract_t">Chambers SM, Goodell MA. Hematopoietic stem cell aging: wrinkles in stem cell potential. Stem Cell Rev 2007; 3:201.</a></li><li><a class="nounderline abstract_t">Shaw AC, Joshi S, Greenwood H, et al. Aging of the innate immune system. Curr Opin Immunol 2010; 22:507.</a></li><li><a class="nounderline abstract_t">Boehmer ED, Goral J, Faunce DE, Kovacs EJ. Age-dependent decrease in Toll-like receptor 4-mediated proinflammatory cytokine production and mitogen-activated protein kinase expression. J Leukoc Biol 2004; 75:342.</a></li><li><a class="nounderline abstract_t">van Duin D, Mohanty S, Thomas V, et al. Age-associated defect in human TLR-1/2 function. J Immunol 2007; 178:970.</a></li><li><a class="nounderline abstract_t">Ogawa T, Kitagawa M, Hirokawa K. Age-related changes of human bone marrow: a histometric estimation of proliferative cells, apoptotic cells, T cells, B cells and macrophages. Mech Ageing Dev 2000; 117:57.</a></li><li><a class="nounderline abstract_t">Plowden J, Renshaw-Hoelscher M, Engleman C, et al. Innate immunity in aging: impact on macrophage function. Aging Cell 2004; 3:161.</a></li><li><a class="nounderline abstract_t">Agius E, Lacy KE, Vukmanovic-Stejic M, et al. Decreased TNF-alpha synthesis by macrophages restricts cutaneous immunosurveillance by memory CD4+ T cells during aging. J Exp Med 2009; 206:1929.</a></li><li><a class="nounderline abstract_t">Gomez CR, Nomellini V, Faunce DE, Kovacs EJ. Innate immunity and aging. Exp Gerontol 2008; 43:718.</a></li><li><a class="nounderline abstract_t">Wessels I, Jansen J, Rink L, Uciechowski P. Immunosenescence of polymorphonuclear neutrophils. ScientificWorldJournal 2010; 10:145.</a></li><li><a class="nounderline abstract_t">Panda A, Arjona A, Sapey E, et al. Human innate immunosenescence: causes and consequences for immunity in old age. Trends Immunol 2009; 30:325.</a></li><li><a class="nounderline abstract_t">Borrego F, Alonso MC, Galiani MD, et al. NK phenotypic markers and IL2 response in NK cells from elderly people. Exp Gerontol 1999; 34:253.</a></li><li><a class="nounderline abstract_t">Hayhoe RP, Henson SM, Akbar AN, Palmer DB. Variation of human natural killer cell phenotypes with age: identification of a unique KLRG1-negative subset. Hum Immunol 2010; 71:676.</a></li><li><a class="nounderline abstract_t">Przemska-Kosicka A, Childs CE, Maidens C, et al. Age-Related Changes in the Natural Killer Cell Response to Seasonal Influenza Vaccination Are Not Influenced by a Synbiotic: a Randomised Controlled Trial. Front Immunol 2018; 9:591.</a></li><li><a class="nounderline abstract_t">Le Garff-Tavernier M, Béziat V, Decocq J, et al. Human NK cells display major phenotypic and functional changes over the life span. Aging Cell 2010; 9:527.</a></li><li><a class="nounderline abstract_t">Ogata K, An E, Shioi Y, et al. Association between natural killer cell activity and infection in immunologically normal elderly people. Clin Exp Immunol 2001; 124:392.</a></li><li><a class="nounderline abstract_t">Sansoni P, Cossarizza A, Brianti V, et al. Lymphocyte subsets and natural killer cell activity in healthy old people and centenarians. Blood 1993; 82:2767.</a></li><li><a class="nounderline abstract_t">Berzins SP, Smyth MJ, Baxter AG. Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol 2011; 11:131.</a></li><li><a class="nounderline abstract_t">Zajonc DM, Kronenberg M. Carbohydrate specificity of the recognition of diverse glycolipids by natural killer T cells. Immunol Rev 2009; 230:188.</a></li><li><a class="nounderline abstract_t">DelaRosa O, Tarazona R, Casado JG, et al. Valpha24+ NKT cells are decreased in elderly humans. Exp Gerontol 2002; 37:213.</a></li><li><a class="nounderline abstract_t">Jing Y, Gravenstein S, Chaganty NR, et al. Aging is associated with a rapid decline in frequency, alterations in subset composition, and enhanced Th2 response in CD1d-restricted NKT cells from human peripheral blood. Exp Gerontol 2007; 42:719.</a></li><li><a class="nounderline abstract_t">Peralbo E, DelaRosa O, Gayoso I, et al. Decreased frequency and proliferative response of invariant Valpha24Vbeta11 natural killer T (iNKT) cells in healthy elderly. Biogerontology 2006; 7:483.</a></li><li><a class="nounderline abstract_t">Agrawal A, Agrawal S, Gupta S. Dendritic cells in human aging. Exp Gerontol 2007; 42:421.</a></li><li><a class="nounderline abstract_t">Jing Y, Shaheen E, Drake RR, et al. Aging is associated with a numerical and functional decline in plasmacytoid dendritic cells, whereas myeloid dendritic cells are relatively unaltered in human peripheral blood. Hum Immunol 2009; 70:777.</a></li><li><a class="nounderline abstract_t">Panda A, Qian F, Mohanty S, et al. Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J Immunol 2010; 184:2518.</a></li><li><a class="nounderline abstract_t">Zacca ER, Crespo MI, Acland RP, et al. Aging Impairs the Ability of Conventional Dendritic Cells to Cross-Prime CD8+ T Cells upon Stimulation with a TLR7 Ligand. PLoS One 2015; 10:e0140672.</a></li><li><a class="nounderline abstract_t">Flores KG, Li J, Sempowski GD, et al. Analysis of the human thymic perivascular space during aging. J Clin Invest 1999; 104:1031.</a></li><li><a class="nounderline abstract_t">Naylor K, Li G, Vallejo AN, et al. The influence of age on T cell generation and TCR diversity. J Immunol 2005; 174:7446.</a></li><li><a class="nounderline abstract_t">Nasi M, Troiano L, Lugli E, et al. Thymic output and functionality of the IL-7/IL-7 receptor system in centenarians: implications for the neolymphogenesis at the limit of human life. Aging Cell 2006; 5:167.</a></li><li><a class="nounderline abstract_t">Li G, Yu M, Lee WW, et al. Decline in miR-181a expression with age impairs T cell receptor sensitivity by increasing DUSP6 activity. Nat Med 2012; 18:1518.</a></li><li><a class="nounderline abstract_t">Kaltoft K. Cytokine-driven immortalization of in vitro activated human T lymphocytes. CD28 expression correlates inversely with cell population doublings. Exp Clin Immunogenet 1998; 15:84.</a></li><li><a class="nounderline abstract_t">Haynes L, Maue AC. Effects of aging on T cell function. Curr Opin Immunol 2009; 21:414.</a></li><li><a class="nounderline abstract_t">Tsaknaridis L, Spencer L, Culbertson N, et al. Functional assay for human CD4+CD25+ Treg cells reveals an age-dependent loss of suppressive activity. J Neurosci Res 2003; 74:296.</a></li><li><a class="nounderline abstract_t">Uciechowski P, Kahmann L, Plümäkers B, et al. TH1 and TH2 cell polarization increases with aging and is modulated by zinc supplementation. Exp Gerontol 2008; 43:493.</a></li><li><a class="nounderline abstract_t">Cakman I, Rohwer J, Schütz RM, et al. Dysregulation between TH1 and TH2 T cell subpopulations in the elderly. Mech Ageing Dev 1996; 87:197.</a></li><li><a class="nounderline abstract_t">Mansfield AS, Nevala WK, Dronca RS, et al. Normal ageing is associated with an increase in Th2 cells, MCP-1 (CCL1) and RANTES (CCL5), with differences in sCD40L and PDGF-AA between sexes. Clin Exp Immunol 2012; 170:186.</a></li><li><a class="nounderline abstract_t">Sakata-Kaneko S, Wakatsuki Y, Matsunaga Y, et al. Altered Th1/Th2 commitment in human CD4+ T cells with ageing. Clin Exp Immunol 2000; 120:267.</a></li><li><a class="nounderline abstract_t">Marcos-Pérez D, Sánchez-Flores M, Maseda A, et al. Frailty in Older Adults Is Associated With Plasma Concentrations of Inflammatory Mediators but Not With Lymphocyte Subpopulations. Front Immunol 2018; 9:1056.</a></li><li><a class="nounderline abstract_t">Frasca D, Blomberg BB. Effects of aging on B cell function. Curr Opin Immunol 2009; 21:425.</a></li><li><a class="nounderline abstract_t">Frasca D, Landin AM, Lechner SC, et al. Aging down-regulates the transcription factor E2A, activation-induced cytidine deaminase, and Ig class switch in human B cells. J Immunol 2008; 180:5283.</a></li><li><a class="nounderline abstract_t">Lazuardi L, Jenewein B, Wolf AM, et al. Age-related loss of naïve T cells and dysregulation of T-cell/B-cell interactions in human lymph nodes. Immunology 2005; 114:37.</a></li><li><a class="nounderline abstract_t">Gibson KL, Wu YC, Barnett Y, et al. B-cell diversity decreases in old age and is correlated with poor health status. Aging Cell 2009; 8:18.</a></li><li><a class="nounderline abstract_t">Henson SM, Akbar AN. Memory T-cell homeostasis and senescence during aging. Adv Exp Med Biol 2010; 684:189.</a></li><li><a class="nounderline abstract_t">Stacy S, Krolick KA, Infante AJ, Kraig E. Immunological memory and late onset autoimmunity. Mech Ageing Dev 2002; 123:975.</a></li><li><a class="nounderline abstract_t">Kovaiou RD, Weiskirchner I, Keller M, et al. Age-related differences in phenotype and function of CD4+ T cells are due to a phenotypic shift from naive to memory effector CD4+ T cells. Int Immunol 2005; 17:1359.</a></li><li><a class="nounderline abstract_t">Hancock K, Veguilla V, Lu X, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009; 361:1945.</a></li><li><a class="nounderline abstract_t">Monsalvo AC, Batalle JP, Lopez MF, et al. Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nat Med 2011; 17:195.</a></li><li><a class="nounderline abstract_t">Haynes L, Eaton SM, Burns EM, et al. Newly generated CD4 T cells in aged animals do not exhibit age-related defects in response to antigen. J Exp Med 2005; 201:845.</a></li><li><a class="nounderline abstract_t">Wagner A, Garner-Spitzer E, Jasinska J, et al. Age-related differences in humoral and cellular immune responses after primary immunisation: indications for stratified vaccination schedules. Sci Rep 2018; 8:9825.</a></li><li><a class="nounderline abstract_t">Weinberger B, Haks MC, de Paus RA, et al. Impaired Immune Response to Primary but Not to Booster Vaccination Against Hepatitis B in Older Adults. Front Immunol 2018; 9:1035.</a></li><li><a class="nounderline abstract_t">Brodin P, Jojic V, Gao T, et al. Variation in the human immune system is largely driven by non-heritable influences. Cell 2015; 160:37.</a></li><li><a class="nounderline abstract_t">Karagiannis TT, Dowrey TW, Villacorta-Martin C, et al. Multi-modal profiling of peripheral blood cells across the human lifespan reveals distinct immune cell signatures of aging and longevity. EBioMedicine 2023; 90:104514.</a></li><li><a class="nounderline abstract_t">Levine ME, Lu AT, Quach A, et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging (Albany NY) 2018; 10:573.</a></li><li><a class="nounderline abstract_t">Lu AT, Quach A, Wilson JG, et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. Aging (Albany NY) 2019; 11:303.</a></li><li><a class="nounderline abstract_t">Belsky DW, Caspi A, Corcoran DL, et al. DunedinPACE, a DNA methylation biomarker of the pace of aging. Elife 2022; 11.</a></li><li><a class="nounderline abstract_t">Poganik JR, Zhang B, Baht GS, et al. Biological age is increased by stress and restored upon recovery. Cell Metab 2023; 35:807.</a></li><li><a class="nounderline abstract_t">Yang JH, Hayano M, Griffin PT, et al. Loss of epigenetic information as a cause of mammalian aging. Cell 2023; 186:305.</a></li><li><a class="nounderline abstract_t">Waziry R, Ryan CP, Corcoran DL, et al. Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial. Nat Aging 2023; 3:248.</a></li><li><a class="nounderline abstract_t">Katsimpardi L, Litterman NK, Schein PA, et al. Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors. Science 2014; 344:630.</a></li><li><a class="nounderline abstract_t">Conboy IM, Conboy MJ, Wagers AJ, et al. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature 2005; 433:760.</a></li><li><a class="nounderline abstract_t">Horowitz AM, Fan X, Bieri G, et al. Blood factors transfer beneficial effects of exercise on neurogenesis and cognition to the aged brain. Science 2020; 369:167.</a></li><li><a class="nounderline abstract_t">Lehallier B, Gate D, Schaum N, et al. Undulating changes in human plasma proteome profiles across the lifespan. Nat Med 2019; 25:1843.</a></li><li><a class="nounderline abstract_t">Furman D, Chang J, Lartigue L, et al. Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and immunological states. Nat Med 2017; 23:174.</a></li><li><a class="nounderline abstract_t">Kaszubowska L. Telomere shortening and ageing of the immune system. J Physiol Pharmacol 2008; 59 Suppl 9:169.</a></li><li><a class="nounderline abstract_t">Risques RA, Arbeev KG, Yashin AI, et al. Leukocyte telomere length is associated with disability in older u.s. Population. J Am Geriatr Soc 2010; 58:1289.</a></li><li><a class="nounderline abstract_t">Arai Y, Martin-Ruiz CM, Takayama M, et al. Inflammation, But Not Telomere Length, Predicts Successful Ageing at Extreme Old Age: A Longitudinal Study of Semi-supercentenarians. EBioMedicine 2015; 2:1549.</a></li><li><a class="nounderline abstract_t">Horvath S, Pirazzini C, Bacalini MG, et al. Decreased epigenetic age of PBMCs from Italian semi-supercentenarians and their offspring. Aging (Albany NY) 2015; 7:1159.</a></li><li><a class="nounderline abstract_t">Koch S, Larbi A, Ozcelik D, et al. Cytomegalovirus infection: a driving force in human T cell immunosenescence. Ann N Y Acad Sci 2007; 1114:23.</a></li><li><a class="nounderline abstract_t">Thomasini RL, Pereira DS, Pereira FSM, et al. Aged-associated cytomegalovirus and Epstein-Barr virus reactivation and cytomegalovirus relationship with the frailty syndrome in older women. PLoS One 2017; 12:e0180841.</a></li><li><a class="nounderline abstract_t">Pawelec G, Ferguson FG, Wikby A. The SENIEUR protocol after 16 years. Mech Ageing Dev 2001; 122:132.</a></li><li><a class="nounderline abstract_t">Wikby A, Johansson B, Ferguson F, Olsson J. Age-related changes in immune parameters in a very old population of Swedish people: a longitudinal study. Exp Gerontol 1994; 29:531.</a></li><li><a class="nounderline abstract_t">Pawelec G, Ouyang Q, Colonna-Romano G, et al. Is human immunosenescence clinically relevant? Looking for 'immunological risk phenotypes'. Trends Immunol 2002; 23:330.</a></li><li><a class="nounderline abstract_t">Derhovanessian E, Maier AB, Beck R, et al. Hallmark features of immunosenescence are absent in familial longevity. J Immunol 2010; 185:4618.</a></li><li><a class="nounderline abstract_t">Strindhall J, Nilsson BO, Löfgren S, et al. No Immune Risk Profile among individuals who reach 100 years of age: findings from the Swedish NONA immune longitudinal study. Exp Gerontol 2007; 42:753.</a></li><li><a class="nounderline abstract_t">Collerton J, Martin-Ruiz C, Davies K, et al. Frailty and the role of inflammation, immunosenescence and cellular ageing in the very old: cross-sectional findings from the Newcastle 85+ Study. Mech Ageing Dev 2012; 133:456.</a></li><li><a class="nounderline abstract_t">Adriaensen W, Derhovanessian E, Vaes B, et al. CD4:8 ratio &gt;5 is associated with a dominant naive T-cell phenotype and impaired physical functioning in CMV-seropositive very elderly people: results from the BELFRAIL study. J Gerontol A Biol Sci Med Sci 2015; 70:143.</a></li><li><a class="nounderline abstract_t">Strindhall J, Skog M, Ernerudh J, et al. The inverted CD4/CD8 ratio and associated parameters in 66-year-old individuals: the Swedish HEXA immune study. Age (Dordr) 2013; 35:985.</a></li><li><a class="nounderline abstract_t">Strindhall J, Löfgren S, Främsth C, et al. CD4/CD8 ratio&lt;1 is associated with lymphocyte subsets, CMV and gender in 71-year old individuals: 5-Year follow-up of the Swedish HEXA Immune Longitudinal Study. Exp Gerontol 2017; 95:82.</a></li><li><a class="nounderline abstract_t">Maggini S, Wintergerst ES, Beveridge S, Hornig DH. Selected vitamins and trace elements support immune function by strengthening epithelial barriers and cellular and humoral immune responses. Br J Nutr 2007; 98 Suppl 1:S29.</a></li><li><a class="nounderline abstract_t">High KP. Micronutrient supplementation and immune function in the elderly. Clin Infect Dis 1999; 28:717.</a></li><li><a class="nounderline abstract_t">Chandra RK. Impact of nutritional status and nutrient supplements on immune responses and incidence of infection in older individuals. Ageing Res Rev 2004; 3:91.</a></li><li><a class="nounderline abstract_t">Gibson A, Edgar JD, Neville CE, et al. Effect of fruit and vegetable consumption on immune function in older people: a randomized controlled trial. Am J Clin Nutr 2012; 96:1429.</a></li><li><a class="nounderline abstract_t">DiPenta JM, Johnson JG, Murphy RJ. Natural killer cells and exercise training in the elderly: a review. Can J Appl Physiol 2004; 29:419.</a></li><li><a class="nounderline abstract_t">Ogawa K, Oka J, Yamakawa J, Higuchi M. A single bout of exercise influences natural killer cells in elderly women, especially those who are habitually active. J Strength Cond Res 2005; 19:45.</a></li><li><a class="nounderline abstract_t">Kohut ML, Arntson BA, Lee W, et al. Moderate exercise improves antibody response to influenza immunization in older adults. Vaccine 2004; 22:2298.</a></li><li><a class="nounderline abstract_t">van der Geest KSM, Wang Q, Eijsvogels TMH, et al. Changes in peripheral immune cell numbers and functions in octogenarian walkers - an acute exercise study. Immun Ageing 2017; 14:5.</a></li><li><a class="nounderline abstract_t">Abd El-Kader SM, Al-Shreef FM. Inflammatory cytokines and immune system modulation by aerobic versus resisted exercise training for elderly. Afr Health Sci 2018; 18:120.</a></li><li><a class="nounderline abstract_t">Duggal NA, Pollock RD, Lazarus NR, et al. Major features of immunesenescence, including reduced thymic output, are ameliorated by high levels of physical activity in adulthood. Aging Cell 2018; 17.</a></li><li><a class="nounderline abstract_t">Haaland DA, Sabljic TF, Baribeau DA, et al. Is regular exercise a friend or foe of the aging immune system? A systematic review. Clin J Sport Med 2008; 18:539.</a></li><li><a class="nounderline abstract_t">Bauer ME, Muller GC, Correa BL, et al. Psychoneuroendocrine interventions aimed at attenuating immunosenescence: a review. Biogerontology 2013; 14:9.</a></li><li><a class="nounderline abstract_t">Busse WW, Peters SP, Fenton MJ, et al. Vaccination of patients with mild and severe asthma with a 2009 pandemic H1N1 influenza virus vaccine. J Allergy Clin Immunol 2011; 127:130.</a></li><li><a class="nounderline abstract_t">Iob A, Brianti G, Zamparo E, Gallo T. Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy. Epidemiol Infect 2005; 133:687.</a></li><li><a class="nounderline abstract_t">Li R, Fang H, Li Y, et al. Safety and immunogenicity of an MF59-adjuvanted subunit influenza vaccine in elderly Chinese subjects. Immun Ageing 2008; 5:2.</a></li><li><a class="nounderline abstract_t">de Roux A, Schmöle-Thoma B, Siber GR, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008; 46:1015.</a></li><li><a class="nounderline abstract_t">Hsu HE, Shutt KA, Moore MR, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 2009; 360:244.</a></li><li><a class="nounderline abstract_t">Roos D, Homan-Müller JW, Weening RS. Effect of cytochalasin B on the oxidative metabolism of human peripheral blood granulocytes. Biochem Biophys Res Commun 1976; 68:43.</a></li><li><a class="nounderline abstract_t">Sankilampi U, Honkanen PO, Bloigu A, et al. Antibody response to pneumococcal capsular polysaccharide vaccine in the elderly. J Infect Dis 1996; 173:387.</a></li><li><a class="nounderline abstract_t">Romero-Steiner S, Musher DM, Cetron MS, et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis 1999; 29:281.</a></li><li><a class="nounderline abstract_t">Andrews NJ, Waight PA, George RC, et al. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine 2012; 30:6802.</a></li><li><a class="nounderline abstract_t">van Werkhoven CH, Huijts SM, Bolkenbaas M, et al. The Impact of Age on the Efficacy of 13-valent Pneumococcal Conjugate Vaccine in Elderly. Clin Infect Dis 2015; 61:1835.</a></li><li><a class="nounderline abstract_t">Djennad A, Ramsay ME, Pebody R, et al. Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine and Changes in Invasive Pneumococcal Disease Incidence from 2000 to 2017 in Those Aged 65 and Over in England and Wales. EClinicalMedicine 2018; 6:42.</a></li><li><a class="nounderline abstract_t">Nuñez IA, Carlock MA, Allen JD, et al. Impact of age and pre-existing influenza immune responses in humans receiving split inactivated influenza vaccine on the induction of the breadth of antibodies to influenza A strains. PLoS One 2017; 12:e0185666.</a></li><li><a class="nounderline abstract_t">Dooling KL, Guo A, Patel M, et al. Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. MMWR Morb Mortal Wkly Rep 2018; 67:103.</a></li><li><a class="nounderline abstract_t">Anderson TC, Masters NB, Guo A, et al. Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep 2022; 71:80.</a></li><li><a class="nounderline abstract_t">Kaml M, Weiskirchner I, Keller M, et al. Booster vaccination in the elderly: their success depends on the vaccine type applied earlier in life as well as on pre-vaccination antibody titers. Vaccine 2006; 24:6808.</a></li><li><a class="nounderline abstract_t">Couch RB, Bayas JM, Caso C, et al. Superior antigen-specific CD4+ T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older. BMC Infect Dis 2014; 14:425.</a></li><li><a class="nounderline abstract_t">Steinhagen F, Kinjo T, Bode C, Klinman DM. TLR-based immune adjuvants. Vaccine 2011; 29:3341.</a></li><li><a class="nounderline abstract_t">Holland D, Booy R, De Looze F, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 2008; 198:650.</a></li><li><a class="nounderline abstract_t">Mackall CL, Fry TJ, Gress RE. Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol 2011; 11:330.</a></li><li><a class="nounderline abstract_t">Sportès C, Hakim FT, Memon SA, et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med 2008; 205:1701.</a></li><li><a class="nounderline abstract_t">Levy Y, Lacabaratz C, Weiss L, et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 2009; 119:997.</a></li><li><a class="nounderline abstract_t">Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009; 460:392.</a></li><li><a class="nounderline abstract_t">Miller RA, Harrison DE, Astle CM, et al. Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging Cell 2014; 13:468.</a></li><li><a class="nounderline abstract_t">Tardif S, Ross C, Bergman P, et al. Testing efficacy of administration of the antiaging drug rapamycin in a nonhuman primate, the common marmoset. J Gerontol A Biol Sci Med Sci 2015; 70:577.</a></li><li><a class="nounderline abstract_t">Mannick JB, Del Giudice G, Lattanzi M, et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med 2014; 6:268ra179.</a></li><li><a class="nounderline abstract_t">Lages CS, Lewkowich I, Sproles A, et al. Partial restoration of T-cell function in aged mice by in vitro blockade of the PD-1/ PD-L1 pathway. Aging Cell 2010; 9:785.</a></li><li><a class="nounderline abstract_t">Wang TW, Johmura Y, Suzuki N, et al. Blocking PD-L1-PD-1 improves senescence surveillance and ageing phenotypes. Nature 2022; 611:358.</a></li><li><a class="nounderline abstract_t">Kim CM, Lee JB, Shin SJ, et al. The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression. ESMO Open 2022; 7:100577.</a></li><li><a class="nounderline abstract_t">Davaro F, Forde SD, Garfield M, et al. 3-Hydroxyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin)-induced 28-kDa interleukin-1β interferes with mature IL-1β signaling. J Biol Chem 2014; 289:16214.</a></li><li><a class="nounderline abstract_t">Ruiz-Limon P, Barbarroja N, Perez-Sanchez C, et al. Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment. Ann Rheum Dis 2015; 74:1450.</a></li><li><a class="nounderline abstract_t">Lyons A, Murphy KJ, Clarke R, Lynch MA. Atorvastatin prevents age-related and amyloid-β-induced microglial activation by blocking interferon-γ release from natural killer cells in the brain. J Neuroinflammation 2011; 8:27.</a></li><li><a class="nounderline abstract_t">Olivieri F, Mazzanti I, Abbatecola AM, et al. Telomere/Telomerase system: a new target of statins pleiotropic effect? Curr Vasc Pharmacol 2012; 10:216.</a></li><li><a class="nounderline abstract_t">Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia 2017; 60:1577.</a></li><li><a class="nounderline abstract_t">Bannister CA, Holden SE, Jenkins-Jones S, et al. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes Obes Metab 2014; 16:1165.</a></li><li><a class="nounderline abstract_t">Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a Tool to Target Aging. Cell Metab 2016; 23:1060.</a></li><li><a class="nounderline abstract_t">Kumari S, Bubak MT, Schoenberg HM, et al. Antecedent Metabolic Health and Metformin (ANTHEM) Aging Study: Rationale and Study Design for a Randomized Controlled Trial. J Gerontol A Biol Sci Med Sci 2022; 77:2373.</a></li><li><a class="nounderline abstract_t">Siegrist CA, Aspinall R. B-cell responses to vaccination at the extremes of age. Nat Rev Immunol 2009; 9:185.</a></li><li><a class="nounderline abstract_t">Weinberger B, Herndler-Brandstetter D, Schwanninger A, et al. Biology of immune responses to vaccines in elderly persons. Clin Infect Dis 2008; 46:1078.</a></li><li><a class="nounderline abstract_t">Schenkein JG, Park S, Nahm MH. Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency. Vaccine 2008; 26:5521.</a></li><li><a class="nounderline abstract_t">Musher DM, Manof SB, Liss C, et al. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis 2010; 201:516.</a></li><li><a class="nounderline abstract_t">Ridda I, Macintyre CR, Lindley R, et al. Immunological responses to pneumococcal vaccine in frail older people. Vaccine 2009; 27:1628.</a></li></ol></div><div id="topicVersionRevision">Topic 13568 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32386655" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Influence of immune aging on vaccine responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20377107" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Innate and adaptive immunosenescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30046148" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Inflammaging: a new immune-metabolic viewpoint for age-related diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28416161" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Cellular Senescence: A Translational Perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31838837" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Senolytics and Senostatics: A Two-Pronged Approach to Target Cellular Senescence for Delaying Aging and Age-Related Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31838837" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Senolytics and Senostatics: A Two-Pronged Approach to Target Cellular Senescence for Delaying Aging and Age-Related Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12409046" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Ageing and infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10913413" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Fever in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15291092" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Geriatric failure to thrive.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8919675" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The dwindles: failure to thrive in older patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21271475" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : [Malnutrition in the elderly].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18044074" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Immunosupportive therapies in aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12473011" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Nutritional status using mini nutritional assessment and subjective global assessment predict mortality in geriatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20424807" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Undiagnosed malnutrition and nutrition-related problems in geriatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10228987" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Reduced immune function and malnutrition in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12142969" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Nutrition and the immune system from birth to old age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11327745" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Serum levels assessment of vitamin A, E, C, B2 and carotenoids in malnourished and non-malnourished hospitalized elderly patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8194493" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Requirement and supply of vitamin C, E and beta-carotene for elderly men and women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12716678" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Screening for vitamin B-12 and folate deficiency in older persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15289425" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Vitamin B12 (cobalamin) deficiency in elderly patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17260529" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Vitamin B6 status, deficiency and its consequences--an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7474272" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Vitamin D deficiency in homebound elderly persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12166371" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Magnesium and trace elements in the elderly: intake, status and recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18809092" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Nutritional anemias and the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19577481" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The role of immunity in elderly cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18422728" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Ageing is associated with diminished apoptotic cell clearance in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15288004" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Systemic autoimmune diseases in elderly patients: atypical presentation and association with neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29854851" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A Cross-Sectional Study of the Association between Autoantibodies and Qualitative Ultrasound Index of Bone in an Elderly Sample without Clinical Autoimmune Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32972996" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Autoantibodies against type I IFNs in patients with life-threatening COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34413139" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4038365" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The clinical features of elderly-onset rheumatoid arthritis. A comparison with younger-onset disease of similar duration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19624493" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The aging of the immune system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19540806" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Aging in the lympho-hematopoietic stem cell compartment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7937905" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19540810" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : B cells and aging: molecules and mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17917133" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Hematopoietic stem cell aging: wrinkles in stem cell potential.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20667703" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Aging of the innate immune system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14634059" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Age-dependent decrease in Toll-like receptor 4-mediated proinflammatory cytokine production and mitogen-activated protein kinase expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17202359" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Age-associated defect in human TLR-1/2 function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10958923" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Age-related changes of human bone marrow: a histometric estimation of proliferative cells, apoptotic cells, T cells, B cells and macrophages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15268749" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Innate immunity in aging: impact on macrophage function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19667063" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Decreased TNF-alpha synthesis by macrophages restricts cutaneous immunosurveillance by memory CD4+ T cells during aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18586079" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Innate immunity and aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20098958" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Immunosenescence of polymorphonuclear neutrophils.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19541535" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Human innate immunosenescence: causes and consequences for immunity in old age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10363791" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : NK phenotypic markers and IL2 response in NK cells from elderly people.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20394788" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Variation of human natural killer cell phenotypes with age: identification of a unique KLRG1-negative subset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29662493" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Age-Related Changes in the Natural Killer Cell Response to Seasonal Influenza Vaccination Are Not Influenced by a Synbiotic: a Randomised Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20477761" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Human NK cells display major phenotypic and functional changes over the life span.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11472399" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Association between natural killer cell activity and infection in immunologically normal elderly people.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8219229" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Lymphocyte subsets and natural killer cell activity in healthy old people and centenarians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21267014" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Presumed guilty: natural killer T cell defects and human disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19594637" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Carbohydrate specificity of the recognition of diverse glycolipids by natural killer T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11772506" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Valpha24+ NKT cells are decreased in elderly humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17368996" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Aging is associated with a rapid decline in frequency, alterations in subset composition, and enhanced Th2 response in CD1d-restricted NKT cells from human peripheral blood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16953330" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Decreased frequency and proliferative response of invariant Valpha24Vbeta11 natural killer T (iNKT) cells in healthy elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17182207" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Dendritic cells in human aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19596035" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Aging is associated with a numerical and functional decline in plasmacytoid dendritic cells, whereas myeloid dendritic cells are relatively unaltered in human peripheral blood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20100933" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26474053" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Aging Impairs the Ability of Conventional Dendritic Cells to Cross-Prime CD8+ T Cells upon Stimulation with a TLR7 Ligand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10525041" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Analysis of the human thymic perivascular space during aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15905594" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The influence of age on T cell generation and TCR diversity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16626395" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Thymic output and functionality of the IL-7/IL-7 receptor system in centenarians: implications for the neolymphogenesis at the limit of human life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23023500" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Decline in miR-181a expression with age impairs T cell receptor sensitivity by increasing DUSP6 activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9691202" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Cytokine-driven immortalization of in vitro activated human T lymphocytes. CD28 expression correlates inversely with cell population doublings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19500967" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Effects of aging on T cell function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14515359" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Functional assay for human CD4+CD25+ Treg cells reveals an age-dependent loss of suppressive activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18166287" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : TH1 and TH2 cell polarization increases with aging and is modulated by zinc supplementation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8794447" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Dysregulation between TH1 and TH2 T cell subpopulations in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23039889" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Normal ageing is associated with an increase in Th2 cells, MCP-1 (CCL1) and RANTES (CCL5), with differences in sCD40L and PDGF-AA between sexes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10792375" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Altered Th1/Th2 commitment in human CD4+ T cells with ageing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29868017" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Frailty in Older Adults Is Associated With Plasma Concentrations of Inflammatory Mediators but Not With Lymphocyte Subpopulations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19608393" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Effects of aging on B cell function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18390709" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Aging down-regulates the transcription factor E2A, activation-induced cytidine deaminase, and Ig class switch in human B cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15606793" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Age-related loss of naïve T cells and dysregulation of T-cell/B-cell interactions in human lymph nodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18986373" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : B-cell diversity decreases in old age and is correlated with poor health status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20795550" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Memory T-cell homeostasis and senescence during aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12044946" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Immunological memory and late onset autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16141244" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Age-related differences in phenotype and function of CD4+ T cells are due to a phenotypic shift from naive to memory effector CD4+ T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19745214" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21131958" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15781577" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Newly generated CD4 T cells in aged animals do not exhibit age-related defects in response to antigen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29959387" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Age-related differences in humoral and cellular immune responses after primary immunisation: indications for stratified vaccination schedules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29868000" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Impaired Immune Response to Primary but Not to Booster Vaccination Against Hepatitis B in Older Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25594173" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Variation in the human immune system is largely driven by non-heritable influences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37005201" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Multi-modal profiling of peripheral blood cells across the human lifespan reveals distinct immune cell signatures of aging and longevity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29676998" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : An epigenetic biomarker of aging for lifespan and healthspan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30669119" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : DNA methylation GrimAge strongly predicts lifespan and healthspan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35029144" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : DunedinPACE, a DNA methylation biomarker of the pace of aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37086720" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Biological age is increased by stress and restored upon recovery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36638792" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Loss of epigenetic information as a cause of mammalian aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37118425" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24797482" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15716955" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Rejuvenation of aged progenitor cells by exposure to a young systemic environment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32646997" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Blood factors transfer beneficial effects of exercise on neurogenesis and cognition to the aged brain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31806903" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Undulating changes in human plasma proteome profiles across the lifespan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28092664" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and immunological states.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19261979" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Telomere shortening and ageing of the immune system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20579170" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Leukocyte telomere length is associated with disability in older u.s. Population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26629551" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Inflammation, But Not Telomere Length, Predicts Successful Ageing at Extreme Old Age: A Longitudinal Study of Semi-supercentenarians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26678252" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Decreased epigenetic age of PBMCs from Italian semi-supercentenarians and their offspring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17986574" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Cytomegalovirus infection: a driving force in human T cell immunosenescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28700679" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Aged-associated cytomegalovirus and Epstein-Barr virus reactivation and cytomegalovirus relationship with the frailty syndrome in older women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11166351" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : The SENIEUR protocol after 16 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7828662" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Age-related changes in immune parameters in a very old population of Swedish people: a longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12103341" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Is human immunosenescence clinically relevant? Looking for 'immunological risk phenotypes'.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20855876" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Hallmark features of immunosenescence are absent in familial longevity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17606347" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : No Immune Risk Profile among individuals who reach 100 years of age: findings from the Swedish NONA immune longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22663935" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Frailty and the role of inflammation, immunosenescence and cellular ageing in the very old: cross-sectional findings from the Newcastle 85+ Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24568932" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : CD4:8 ratio&gt;5 is associated with a dominant naive T-cell phenotype and impaired physical functioning in CMV-seropositive very elderly people: results from the BELFRAIL study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22415616" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : The inverted CD4/CD8 ratio and associated parameters in 66-year-old individuals: the Swedish HEXA immune study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28476585" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : CD4/CD8 ratio&lt;1 is associated with lymphocyte subsets, CMV and gender in 71-year old individuals: 5-Year follow-up of the Swedish HEXA Immune Longitudinal Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17922955" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Selected vitamins and trace elements support immune function by strengthening epithelial barriers and cellular and humoral immune responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10825025" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Micronutrient supplementation and immune function in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15163104" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Impact of nutritional status and nutrient supplements on immune responses and incidence of infection in older individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23134881" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Effect of fruit and vegetable consumption on immune function in older people: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15317983" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Natural killer cells and exercise training in the elderly: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15707382" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : A single bout of exercise influences natural killer cells in elderly women, especially those who are habitually active.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15149789" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Moderate exercise improves antibody response to influenza immunization in older adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28250797" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Changes in peripheral immune cell numbers and functions in octogenarian walkers - an acute exercise study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29977265" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Inflammatory cytokines and immune system modulation by aerobic versus resisted exercise training for elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29517845" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Major features of immunesenescence, including reduced thymic output, are ameliorated by high levels of physical activity in adulthood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19001887" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Is regular exercise a friend or foe of the aging immune system? A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23283592" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Psychoneuroendocrine interventions aimed at attenuating immunosenescence: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21145578" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Vaccination of patients with mild and severe asthma with a 2009 pandemic H1N1 influenza virus vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16050515" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18289372" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Safety and immunogenicity of an MF59-adjuvanted subunit influenza vaccine in elderly Chinese subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18444818" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19144940" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Effect of pneumococcal conjugate vaccine on pneumococcal meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/174568" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Effect of cytochalasin B on the oxidative metabolism of human peripheral blood granulocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8568300" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Antibody response to pneumococcal capsular polysaccharide vaccine in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10476727" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23000122" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26265498" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : The Impact of Age on the Efficacy of 13-valent Pneumococcal Conjugate Vaccine in Elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31193709" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine and Changes in Invasive Pneumococcal Disease Incidence from 2000 to 2017 in Those Aged 65 and Over in England and Wales.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29091724" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Impact of age and pre-existing influenza immune responses in humans receiving split inactivated influenza vaccine on the induction of the breadth of antibodies to influenza A strains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29370152" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35051134" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16872725" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Booster vaccination in the elderly: their success depends on the vaccine type applied earlier in life as well as on pre-vaccination antibody titers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25078387" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Superior antigen-specific CD4+ T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20713100" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : TLR-based immune adjuvants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18652550" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21508983" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Harnessing the biology of IL-7 for therapeutic application.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18573906" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19287090" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19587680" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Rapamycin fed late in life extends lifespan in genetically heterogeneous mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24341993" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25038772" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Testing efficacy of administration of the antiaging drug rapamycin in a nonhuman primate, the common marmoset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25540326" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : mTOR inhibition improves immune function in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20653631" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Partial restoration of T-cell function in aged mice by in vitro blockade of the PD-1/ PD-L1 pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36323784" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Blocking PD-L1-PD-1 improves senescence surveillance and ageing phenotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36156450" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24790079" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : 3-Hydroxyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin)-induced 28-kDa interleukin-1βinterferes with mature IL-1βsignaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24658835" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21453520" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Atorvastatin prevents age-related and amyloid-β-induced microglial activation by blocking interferon-γrelease from natural killer cells in the brain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22022767" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Telomere/Telomerase system: a new target of statins pleiotropic effect?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28776086" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : The mechanisms of action of metformin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25041462" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27304507" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Metformin as a Tool to Target Aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34865016" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Antecedent Metabolic Health and Metformin (ANTHEM) Aging Study: Rationale and Study Design for a Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19240757" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : B-cell responses to vaccination at the extremes of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18444828" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Biology of immune responses to vaccines in elderly persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18706464" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20092407" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19100304" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Immunological responses to pneumococcal vaccine in frail older people.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
